GT,Diagnosis 1,ERN Category
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with decreased methylmalonyl-CoA mutase activity, metabolic acidosis, and early death. Key symptoms not mentioned: developmental delays, seizures, and other neurological issues.

+2. Propionic acidemia: Consistent with metabolic acidosis and early death. However, the decreased methylmalonyl-CoA mutase activity is more specific to MMA.

+3. Isovaleric acidemia: Consistent with metabolic acidosis and early death. But the enzyme deficiency is not a key feature of this disorder.

+4. Mitochondrial disorder: Consistent with metabolic acidosis and early death. However, the specific enzyme deficiency points more towards an organic acidemia like MMA.

+5. Other inborn error of metabolism: Consistent with metabolic acidosis and early death. But the enzyme deficiency narrows it down to a disorder involving vitamin B12 metabolism, most likely MMA.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Spinal muscular atrophy (SMA): Motor delay, generalized hypotonia, pneumonia. May not always lead to death in infancy.

+2. Leigh syndrome: Motor delay, generalized hypotonia, death in infancy, elevated urinary carboxylic acid.

+3. Pompe disease: Generalized hypotonia, pneumonia, elevated urinary carboxylic acid, death in infancy.

+4. Congenital muscular dystrophy: Motor delay, generalized hypotonia, pneumonia, death in infancy (in severe cases).

+5. Mitochondrial disorder: Motor delay, generalized hypotonia, death in infancy, elevated urinary carboxylic acid (depending on the specific disorder).",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Classic symptom of elevated phenylalanine levels.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential developmental abnormalities or neonatal death. Elevated tyrosine levels are a key feature.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development or birth and potential neonatal death. Specific symptoms depend on the underlying genetic disorder.

+4. Mitochondrial disorder: Consistent with potential developmental abnormalities, neonatal death, and elevated amino acid levels in some cases. Symptoms can vary widely.

+5. Organic acidemia: Consistent with potential developmental abnormalities, neonatal death, and elevated amino acid levels in some cases. Specific symptoms depend on the type of organic acidemia.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Congenital muscular dystrophy: Consistent with motor delay, abnormal muscle physiology, and cerebellar involvement. May not fully explain the diaphragmatic hernia or failure to thrive.

+2. Pontocerebellar hypoplasia: Consistent with cerebellar agenesis/atrophy, motor delay, and failure to thrive. May not account for the diaphragmatic hernia.

+3. Walker-Warburg syndrome: Consistent with congenital diaphragmatic hernia, cerebellar abnormalities, motor delay, and failure to thrive. A rare genetic disorder affecting multiple organ systems.

+4. Congenital disorders of glycosylation: Consistent with a multi-system presentation, including neurological symptoms, failure to thrive, and potential muscle involvement. May or may not involve diaphragmatic hernia.

+5. Severe congenital diaphragmatic hernia with associated brain malformations: Consistent with the diaphragmatic hernia, cerebellar abnormalities, and failure to thrive. May not fully explain the motor delay or abnormal muscle physiology.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Amino acid metabolism disorder: Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, developmental delays, intellectual disability, and potential for early death. May not explain all symptoms like hydronephrosis or kyphoscoliosis.

+2. Neurodegenerative disorder: Consistent with motor delay, generalized hypotonia, athetosis, and potential for early death. May not explain hydronephrosis or elevated amino acid levels.

+3. Genetic syndrome or chromosomal abnormality: Consistent with abnormality of prenatal development or birth, intellectual disability, motor delay, hypotonia, and multiple congenital anomalies. Specific syndrome would depend on the pattern of symptoms.

+4. Congenital anomaly or birth defect: Consistent with hydronephrosis, kyphoscoliosis, and abnormality of prenatal development or birth. May not explain the metabolic or neurological symptoms.

+5. Infectious or inflammatory condition: Consistent with fever, opisthotonus (abnormal posturing), and potential for early death. May not explain the developmental delays or congenital anomalies.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, skin rash, gastrointestinal inflammation, diarrhea, abnormality of prenatal development or birth. Key symptoms not reported: specific neurological or developmental delays associated with the particular metabolic disorder.

+2. Severe combined immunodeficiency (SCID): Recurrent viral infections, abnormality of prenatal development or birth, death in infancy/childhood. Key symptoms not reported: severe or opportunistic infections, failure to thrive, lymphopenia.

+3. Congenital diaphragmatic hernia: Hernia, abnormality of prenatal development or birth. Key symptoms not reported: respiratory distress, pulmonary hypoplasia.

+4. Inflammatory bowel disease (IBD): Gastrointestinal inflammation, diarrhea. Key symptoms not reported: abdominal pain, bloody stools, weight loss.

+5. Severe dermatological condition: Skin rash (erythematous plaque, macule, papule). Key symptoms not reported: specific skin lesions or distribution patterns associated with the particular dermatological condition.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Mitochondrial disease: Consistent with increased lactate levels, potential for severe complications in infancy. Key symptom not reported: muscle weakness, seizures.

+2. Epidermolysis bullosa: Consistent with skin rash, eczematoid dermatitis, alopecia. Key symptom not reported: blistering of skin and mucous membranes.

+3. Ichthyosis: Consistent with skin rash, eczematoid dermatitis, alopecia. Key symptom not reported: scaling or thickening of skin.

+4. Organic acidemia: Consistent with increased lactate levels, potential for severe complications in infancy. Key symptom not reported: developmental delays, seizures.

+5. Lupus erythematosus: Consistent with skin rash, alopecia. Key symptoms not reported: joint pain, fatigue, photosensitivity.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Peroxisomal disorder: Consistent with rod-cone dystrophy, intellectual disability, cerebellar atrophy, abnormal facial features, and hepatic involvement. May not explain lipodystrophy or thromboembolism.

+2. Congenital disorder of glycosylation: Consistent with intellectual disability, cerebellar atrophy, abnormal facial features, and hepatic involvement. May not explain rod-cone dystrophy, lipodystrophy, or thromboembolism.

+3. Mitochondrial disorder: Consistent with rod-cone dystrophy, intellectual disability, cerebellar atrophy, and acute/chronic hepatitis. May not explain abnormal facial features, lipodystrophy, or thromboembolism.

+4. Leukodystrophy: Consistent with intellectual disability, cerebellar atrophy, and abnormal facial features. May not explain rod-cone dystrophy, lipodystrophy, hepatitis, or thromboembolism.

+5. Lysosomal storage disorder: Consistent with intellectual disability, cerebellar atrophy, abnormal facial features, and hepatic involvement. May not explain rod-cone dystrophy, lipodystrophy, or thromboembolism.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, lethargy, hypotonia, dystonia, glutaric aciduria, decreased plasma free carnitine, and potential neonatal death. Key symptom not reported: metabolic acidosis.

+2. Zellweger syndrome: Consistent with macrocephaly, cystic hygroma, hypotonia, and neonatal death. Key symptoms not reported: seizures, liver dysfunction, and characteristic facial features.

+3. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with macrocephaly, hypotonia, dystonia, and neurological symptoms. Key symptoms not reported: vision and hearing loss, seizures, and progressive neurological deterioration.

+4. Congenital infection (e.g., cytomegalovirus, toxoplasmosis): Consistent with macrocephaly, cystic hygroma, fever, vomiting, diarrhea, dyspnea, and neurological symptoms. Key symptoms not reported: rash, jaundice, and specific maternal history.

+5. Mitochondrial disorder: Consistent with lethargy, hypotonia, dystonia, dyskinesia, and potential neonatal death. Key symptoms not reported: lactic acidosis, seizures, and specific biochemical abnormalities.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Glycine encephalopathy: Consistent with abnormal glycine levels, hyperammonemia, lethargy, and neurological symptoms. May not explain feeding difficulties or abnormal carnitine levels.

+2. Carnitine deficiency disorders: Consistent with abnormal carnitine levels, lethargy, and potential hyperammonemia. May not explain abnormal glycine levels or prenatal abnormalities.

+3. Urea cycle disorders: Consistent with hyperammonemia, lethargy, and neurological symptoms. May not explain abnormal glycine or carnitine levels.

+4. Organic acidemias: Consistent with lethargy, neurological symptoms, and potential metabolic abnormalities. May not explain hyperammonemia or abnormal glycine/carnitine levels.

+5. Mitochondrial disorders: Consistent with lethargy, feeding difficulties, and potential metabolic abnormalities. May not explain hyperammonemia or specific amino acid abnormalities.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Joubert syndrome: Consistent with microcephaly, intellectual disability, ataxia, hypotonia, nystagmus, cerebellar agenesis/atrophy, and developmental delays. May also involve breathing abnormalities and kidney problems.

+2. Dandy-Walker malformation: Consistent with cerebellar agenesis/atrophy, intellectual disability, motor delays, hypotonia, and ataxia. May also involve hydrocephalus and other brain abnormalities.

+3. Chromosomal abnormality (e.g., trisomy 18, trisomy 13): Consistent with microcephaly, intellectual disability, growth delay, hypotonia, and multiple congenital anomalies. Specific symptoms may vary depending on the chromosomal disorder.

+4. Inborn error of metabolism (e.g., organic acidemia, aminoacidopathy): Consistent with microcephaly, intellectual disability, encephalopathy, and developmental delays. May also involve seizures, metabolic acidosis, and other systemic symptoms.

+5. Neurodegenerative disorder (e.g., infantile neuroaxonal dystrophy): Consistent with cerebellar atrophy, encephalopathy, hypotonia, and developmental regression. Typically progressive and may involve other neurological symptoms.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Organic acidemia: Consistent with methylmalonic aciduria, hyperammonemia, developmental delays, and potential for early death. Key symptoms not reported: vomiting, lethargy, and metabolic acidosis.

+2. Mitochondrial disorder: Consistent with optic atrophy, nystagmus, developmental delays, hypotonia, and potential for early death. Key symptoms not reported: seizures, lactic acidosis, and muscle weakness.

+3. Congenital disorder of glycosylation (CDG): Consistent with developmental delays, hypotonia, and metabolic abnormalities. Key symptoms not reported: failure to thrive, coagulopathy, and liver dysfunction.

+4. Peroxisomal disorder (e.g., Zellweger syndrome): Consistent with developmental delays, hypotonia, and metabolic abnormalities. Key symptoms not reported: craniofacial dysmorphism, liver dysfunction, and hearing loss.

+5. Amino acid metabolism disorder (e.g., maple syrup urine disease, homocystinuria): Consistent with hyperhomocystinemia, hyperalaninemia, and potential for early death. Key symptoms not reported: maple syrup odor (in maple syrup urine disease), thrombosis (in homocystinuria), and intellectual disability.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with hypoglycemia, vomiting, diarrhea, and abnormal carnitine levels. May not explain elevated transaminases.

+2. Organic acidemia: Consistent with hypoglycemia, vomiting, diarrhea, and abnormal carnitine levels. May not explain elevated transaminases.

+3. Biliary atresia: Consistent with elevated transaminases, vomiting, and diarrhea. May not explain hypoglycemia or abnormal carnitine levels.

+4. Neonatal hepatitis: Consistent with elevated transaminases, vomiting, and diarrhea. May not explain hypoglycemia or abnormal carnitine levels.

+5. Congenital disorder of glycosylation: Consistent with hypoglycemia, vomiting, diarrhea, and elevated transaminases. May not explain abnormal carnitine levels.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid, hyperkalemia, hyponatremia, and potentially severe symptoms like coma and early death. May not explain respiratory acidosis.

+2. Fatty acid oxidation disorder: Consistent with elevated urinary carboxylic acid, hyperkalemia, hyponatremia, and potentially severe symptoms like coma and early death. May not explain respiratory acidosis.

+3. Severe respiratory disorder: Consistent with respiratory acidosis and potentially coma in severe cases. May not explain elevated urinary carboxylic acid or electrolyte imbalances.

+4. Severe neurological condition or brain injury: Consistent with coma and potentially early death. May not explain other symptoms like electrolyte imbalances or elevated urinary carboxylic acid.

+5. Kidney disorder or renal failure: Consistent with electrolyte imbalances (hyperkalemia, hyponatremia) and potentially severe symptoms like coma. May not explain elevated urinary carboxylic acid or respiratory acidosis.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with hyperhomocystinemia, hypermethioninemia, ectopia lentis, intellectual disability, and motor delay. May not explain large hands or long foot.

+2. Congenital disorder of glycosylation: Consistent with intellectual disability, motor delay, connective tissue symptoms (ptosis, ectopia lentis), and potentially metabolic abnormalities. Specific type would need to be determined.

+3. Marfan syndrome: Consistent with ptosis, ectopia lentis, and long limbs (large hands, long foot). Does not typically cause intellectual disability or metabolic issues.

+4. Sotos syndrome: Consistent with intellectual disability, motor delay, large hands, long foot, and fatigue. Does not explain connective tissue or metabolic symptoms.

+5. Undiagnosed syndromic disorder: The combination of symptoms may represent a rare or undiagnosed syndrome involving multiple systems (connective tissue, metabolic, developmental). Further evaluation would be needed.",Hereditary metabolic disorders
[],"+1. Congenital disorders of glycosylation (CDG): Consistent with seizures, hypoglycemia, feeding difficulties, and potentially the developmental features. Key symptoms not reported: specific dysmorphic features, organ involvement.

+2. Maple syrup urine disease (MSUD): Consistent with seizures, hypoglycemia, and feeding difficulties. Key symptoms not reported: maple syrup odor, lethargy, and progressive neurological deterioration.

+3. Trisomy 21 (Down syndrome): Consistent with wide mouth, epicanthus, and sparse hair. Key symptoms not reported: intellectual disability, congenital heart defects, and other characteristic physical features.

+4. Sickle cell disease: Consistent with abnormal hemoglobin. Key symptoms not reported: pain crises, acute chest syndrome, and other complications of the disease.

+5. Inborn error of metabolism (unspecified): Consistent with seizures, hypoglycemia, feeding difficulties, and potentially the developmental features. Additional testing would be needed to identify the specific metabolic disorder.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism: Consistent with hyperammonemia, hyperglycinemia, hypoglycinemia, abnormal circulating carnitine concentration, and neurological symptoms. Key symptoms not reported: specific metabolic abnormalities depending on the disorder.

+2. Mitochondrial disorder: Consistent with intellectual disability, seizures, motor delay, and metabolic abnormalities. Key symptoms not reported: muscle weakness, vision or hearing problems, cardiomyopathy.

+3. Urea cycle disorder: Consistent with hyperammonemia, intellectual disability, seizures, and neonatal/early death. Key symptoms not reported: vomiting, lethargy, respiratory distress.

+4. Organic acidemia: Consistent with intellectual disability, seizures, metabolic abnormalities, and neonatal/early death. Key symptoms not reported: vomiting, lethargy, acidosis, specific metabolic markers.

+5. Chromosomal abnormality or genetic syndrome: Consistent with abnormality of prenatal development, intellectual disability, seizures, and motor delay. Key symptoms not reported: specific dysmorphic features or congenital anomalies.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with metabolic acidosis, methylmalonic aciduria, decreased methylmalonyl-CoA mutase activity, hypotonia, feeding difficulties, and abnormal nervous system physiology. Key symptoms not reported: developmental delay, seizures, and failure to thrive.

+2. Mitochondrial disorder: Consistent with hypotonia, metabolic acidosis, and abnormal nervous system physiology. Key symptoms not reported: muscle weakness, exercise intolerance, and specific neurological manifestations (e.g., ataxia, seizures).

+3. Leukemia or hematological malignancy: Consistent with thrombocytopenia and leukopenia. Key symptoms not reported: fever, fatigue, bruising, and other signs of bone marrow failure.

+4. Sepsis: Consistent with metabolic acidosis, thrombocytopenia, and apnea. Key symptoms not reported: fever, elevated inflammatory markers, and a clear source of infection.

+5. Congenital neuromuscular disorder: Consistent with hypotonia and abnormal nervous system physiology. Key symptoms not reported: specific patterns of muscle weakness or involvement, and other neurological manifestations.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with hypoglycemia, vomiting, abnormal amino acid concentrations. May not explain elevated alkaline phosphatase.

+2. Fatty acid oxidation disorder: Matches hypoglycemia, decreased carnitine. Does not fully account for amino acid abnormalities.

+3. Glycogen storage disease: Explains hypoglycemia, elevated lactate dehydrogenase. Does not fit amino acid and carnitine abnormalities.

+4. Urea cycle disorder: Coma could be due to hyperammonemia, but other symptoms are atypical.

+5. Mitochondrial disorder: Could potentially cause multi-system dysfunction, but specific symptoms are not clearly indicative.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Inborn error of metabolism: Consistent with lethargy, feeding difficulties, decreased plasma free carnitine. Key symptoms not reported: specific metabolic abnormalities, acidosis, hyperammonemia.

+2. Neurodegenerative disorder: Consistent with clumsiness, poor coordination, sleep abnormality. Key symptoms not reported: seizures, vision/hearing loss, cognitive decline.

+3. Congenital muscular disorder: Consistent with lethargy, clumsiness, poor coordination, feeding difficulties. Key symptoms not reported: muscle weakness, respiratory distress, contractures.

+4. Mitochondrial disorder: Consistent with lethargy, poor coordination, feeding difficulties, death in infancy/childhood. Key symptoms not reported: lactic acidosis, seizures, stroke-like episodes.

+5. Congenital brain malformation: Consistent with lethargy, clumsiness, poor coordination, sleep abnormality. Key symptoms not reported: developmental delay, seizures, abnormal head size/shape.",Hereditary metabolic disorders
[],"+1. Cerebral palsy: Consistent with spastic diplegia/tetraplegia, dysarthria, and delayed speech/language development. May not explain all symptoms like encephalopathy or recurrent infections.

+2. Leukodystrophy: Consistent with encephalopathy, spasticity, and developmental delays. May not explain symptoms like hypothyroidism or abnormal glycine levels.

+3. Mitochondrial disorder: Consistent with encephalopathy, cytochrome c oxidase-negative muscle fibers, and potential multi-system involvement. May not explain specific symptoms like spasticity or hypothyroidism.

+4. Glycine encephalopathy: Consistent with encephalopathy and abnormal glycine concentration. May not explain motor symptoms like spasticity or other systemic symptoms.

+5. Combined immunodeficiency disorder: Consistent with recurrent viral infections, which can sometimes be associated with neurological symptoms. May not explain the full spectrum of symptoms reported.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potential developmental abnormalities and early mortality. Key symptoms not reported: specific metabolic derangements, organ involvement.

+2. Congenital malformation: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific details about the malformations.

+3. Chromosomal abnormality: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific chromosomal abnormality, associated dysmorphic features.

+4. Perinatal complications: Abnormality of prenatal development or birth, potential for neonatal death. Key symptoms not reported: specific details about the complications.

+5. Genetic syndrome: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific syndrome features (e.g., dysmorphic features, organ involvement).",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, macrocephaly, hypotonia, dystonia, and potential for early death. May not explain cystic hygroma or neonatal death.

+2. Leigh syndrome: Consistent with neurological symptoms (hypotonia, dystonia), metabolic acidosis, and potential for early death. Does not typically cause glutaric aciduria or cystic hygroma.

+3. Zellweger spectrum disorders: Consistent with neurological symptoms, metabolic abnormalities, macrocephaly, and cystic hygroma. Glutaric aciduria is not a common finding.

+4. Mitochondrial disorders: Consistent with multi-system involvement, metabolic acidosis, and potential for early death. Glutaric aciduria and cystic hygroma are not typical presentations.

+5. Organic acidemia (other than GA1): Consistent with metabolic acidosis, vomiting, lethargy, and potential for early death. May not explain the specific combination of neurological and dysmorphic features.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and developmental abnormalities. Key symptom not reported: musty odor in urine.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential liver and kidney problems. Key symptoms not reported: eye and skin abnormalities, liver disease.

+3. Maple syrup urine disease (MSUD): Consistent with developmental delays and potential amino acid imbalances. Key symptom not reported: maple syrup odor in urine.

+4. Homocystinuria: Consistent with developmental delays and potential vision problems. Key symptoms not reported: blood clots, skeletal abnormalities.

+5. Urea cycle disorders: Consistent with potential neurological problems and developmental delays. Key symptom not reported: elevated ammonia levels in blood.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Leukodystrophy: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running. Key symptom not reported: Vision problems.

+2. Neurodegenerative disorder: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running, death in infancy, death in childhood. Key symptom not reported: Seizures.

+3. Cerebral palsy: Delayed speech and language development, intellectual disability, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running. Key symptoms not reported: Muscle stiffness, abnormal muscle tone.

+4. Chromosomal abnormality: Delayed speech and language development, intellectual disability, difficulty walking, difficulty climbing stairs, difficulty running. Key symptoms not reported: Distinctive physical features, congenital malformations.

+5. Metabolic disorder: Delayed speech and language development, intellectual disability, hyperreflexia, abnormal cerebral white matter morphology, death in infancy, death in childhood. Key symptom not reported: Metabolic acidosis.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, hypoglycemia, and early mortality. Key symptoms not reported: maple syrup odor in urine and cerumen (earwax).

+2. Leigh syndrome: Consistent with apathy, spasticity, generalized hypotonia, and early mortality. Key symptoms not reported: respiratory abnormalities, seizures, and developmental delays.

+3. Prader-Willi syndrome: Consistent with obesity, hypotonia, and developmental delays (implied by apathy). Key symptoms not reported: short stature, hypogonadism, and characteristic facial features.

+4. Mitochondrial encephalomyopathy: Consistent with apathy, spasticity, generalized hypotonia, and early mortality. Key symptoms not reported: seizures, vision and hearing problems, and developmental delays.

+5. Leukodystrophy: Consistent with spasticity, hypotonia, and early mortality. Key symptoms not reported: progressive cognitive and motor decline, seizures, and vision problems.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with hypergalactosemia, abnormality of galactoside metabolism, increased bilirubin, and potential for severe complications. Key symptoms not reported: jaundice, vomiting, liver disease.

+2. Phenylketonuria (PKU): Consistent with hyperalaninemia and developmental delays. Key symptoms not reported: musty odor, fair skin and hair, seizures.

+3. Maple Syrup Urine Disease (MSUD): Consistent with aminoaciduria and abnormal amino acid concentrations. Key symptoms not reported: maple syrup odor, lethargy, seizures.

+4. Intellectual disability or global developmental delay: Consistent with delayed speech and language development, but the metabolic abnormalities suggest an underlying genetic or metabolic cause.

+5. Liver disease or biliary tract disorder: Consistent with increased bilirubin and abnormality of galactoside metabolism, but the specific cause is unclear from the given symptoms.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. May not explain hyperammonemia or abnormal glycine levels.

+2. Urea cycle disorder: Consistent with hyperammonemia and metabolic acidosis. May not explain organic acidurias or abnormal glycine levels.

+3. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration. May not explain organic acidurias or hyperammonemia.

+4. Mitochondrial disorder: Consistent with metabolic acidosis and elevated organic acids. May not explain hyperammonemia or abnormal glycine levels.

+5. Severe liver disease: Consistent with hyperammonemia and metabolic acidosis. May not explain organic acidurias or abnormal glycine levels.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with hyperhomocystinemia, hypomethioninemia, abnormality of folate metabolism, progressive neurologic deterioration, and death in childhood. May not explain jaundice or abnormal porphyrin levels.

+2. Acute intermittent porphyria: Consistent with jaundice, anemia, and abnormal circulating porphyrin concentration. May not explain neurological, metabolic, or immunological symptoms.

+3. Leukodystrophy or neurodegenerative disorder: Consistent with generalized hypotonia, progressive neurologic deterioration, and death in childhood. May not explain metabolic or hematological findings.

+4. Primary immunodeficiency disorder: Consistent with recurrent viral infections. May not explain other symptoms.

+5. Metabolic disorder involving folate and methionine metabolism: Consistent with hyperhomocystinemia, hypomethioninemia, and abnormality of folate metabolism. May not explain all symptoms.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, potential developmental abnormalities, and early death are consistent with conditions like phenylketonuria or tyrosinemia.

+2. Congenital airway anomaly: Upper airway obstruction, potential respiratory complications, and early mortality could be explained by conditions like tracheoesophageal fistula or laryngeal cleft.

+3. Chronic lung disease: Chronic pulmonary obstruction and respiratory failure leading to early death may be seen in conditions like cystic fibrosis or bronchopulmonary dysplasia.

+4. Chromosomal abnormality: Multiple congenital anomalies, developmental delays, and early mortality could be associated with chromosomal disorders like trisomies or deletions.

+5. Multisystem genetic disorder: A range of symptoms affecting multiple organ systems and leading to early death could be indicative of a complex genetic disorder like a metabolic or mitochondrial disease.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with seizures, spasticity, fatigue, and elevated urinary carboxylic acid. May not explain alopecia or dyspnea.

+2. Leukodystrophy (e.g., Krabbe disease): Consistent with seizures, spasticity, and death in infancy. May not explain alopecia, dyspnea, or elevated carboxylic acid.

+3. Fatty acid oxidation disorder: Consistent with seizures, fatigue, and potentially elevated carboxylic acid. May not explain spasticity, alopecia, dyspnea, or death in infancy.

+4. Congenital malformation or chromosomal abnormality: Could potentially explain the broad range of symptoms, but additional details would be needed to narrow down the specific condition.

+5. Mitochondrial disorder: Could potentially cause a combination of neurological, metabolic, and multi-system symptoms, but additional testing would be required to confirm this diagnosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism (e.g., phenylketonuria, tyrosinemia): Consistent with hypertyrosinemia, hyperphenylalaninemia, and potentially other symptoms if left untreated.

+2. Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis): Consistent with gastrointestinal inflammation, fever, and vomiting.

+3. Mitochondrial disorder or lysosomal storage disorder: Consistent with multi-organ involvement, metabolic abnormalities, and potentially early mortality.

+4. Congenital infection (e.g., cytomegalovirus, rubella): Consistent with fever, vomiting, gastrointestinal inflammation, and potentially early mortality.

+5. Malignancy (e.g., leukemia, lymphoma): Consistent with fever, vomiting, and gastrointestinal inflammation, but less likely to cause the specific metabolic abnormalities or early mortality in all cases.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Glycine encephalopathy: Consistent with metabolic acidosis, increased CSF lactate, aminoaciduria, abnormal circulating glycine concentration. Does not typically present with skin rash or alopecia.

+2. Organic acidemia: Consistent with metabolic acidosis, aminoaciduria, elevated urinary carboxylic acid. Does not typically present with skin rash or alopecia.

+3. Erythroderma: Consistent with skin rash (erythematous plaque, macule, papule). Does not explain metabolic abnormalities or aminoaciduria.

+4. Metabolic disorder with cutaneous manifestations: Consistent with skin rash, alopecia, metabolic acidosis, aminoaciduria. Specific condition unclear based on provided symptoms.

+5. Severe drug reaction: Consistent with skin rash (erythematous plaque, macule, papule). Does not explain metabolic abnormalities or aminoaciduria, but could be a potential cause of the rash.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with decreased methylmalonyl-CoA mutase activity, feeding difficulties, dehydration, and potential for neonatal/infant death. Key symptom not reported: metabolic acidosis.

+2. Propionic acidemia: Consistent with feeding difficulties, dehydration, and potential for neonatal/infant death. Key symptoms not reported: vomiting, lethargy, and metabolic acidosis.

+3. Isovaleric acidemia: Consistent with feeding difficulties, dehydration, and potential for neonatal/infant death. Key symptoms not reported: vomiting, acidosis, and a distinctive ""sweaty feet"" odor.

+4. Congenital disorder of glycosylation (CDG): Consistent with feeding difficulties and potential for developmental delays/failure to thrive. Key symptoms not reported: neurological abnormalities, coagulopathy, and specific dysmorphic features.

+5. Mitochondrial disorder: Consistent with feeding difficulties, dehydration, and potential for multi-organ involvement. Key symptoms not reported: specific neurological, muscular, or organ-specific manifestations depending on the affected mitochondrial pathway.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Propionyl-CoA carboxylase deficiency (PCCD): Consistent with metabolic acidosis, increased lactate, decreased pyruvate carboxylase activity, aminoaciduria, elevated urinary carboxylic acid, and the specific mention of this condition. Key symptoms not reported: vomiting, hypoglycemia, and developmental delay.

+2. Methylmalonic acidemia: Consistent with metabolic acidosis, increased lactate, aminoaciduria, and elevated urinary carboxylic acid. Key symptoms not reported: vomiting, failure to thrive, and developmental delay.

+3. Mitochondrial disorder: Consistent with lethargy, hypotonia, metabolic acidosis, increased lactate, and fatigue. Key symptoms not reported: seizures, developmental delay, and specific organ involvement (e.g., cardiomyopathy, myopathy).

+4. Isovaleric acidemia: Consistent with metabolic acidosis, aminoaciduria, and elevated urinary carboxylic acid. Key symptoms not reported: vomiting, sweaty feet odor, and developmental delay.

+5. Sepsis: Consistent with fever, lethargy, and metabolic acidosis. However, the specific metabolic abnormalities and aminoaciduria are not typical of sepsis alone, suggesting an underlying metabolic disorder.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May also present with developmental delays, seizures, and other neurological symptoms not reported.

+2. Tyrosinemia: Consistent with hypertyrosinemia. Can lead to liver disease, neurological problems, and early death if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development. May involve multiple organ systems and cause early mortality.

+4. Severe perinatal asphyxia: Consistent with neonatal death. Can result in organ damage and developmental abnormalities.

+5. Chromosomal abnormality: Consistent with abnormal prenatal development and early mortality. May present with dysmorphic features or other congenital anomalies not reported.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Propionic acidemia: Consistent with death in infancy, dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid.

+2. Multiple carboxylase deficiency: Consistent with death in infancy, dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid.

+3. Methylmalonic acidemia: Consistent with dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. However, death in infancy is not a typical symptom.

+4. Isovaleric acidemia: Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. However, 3-methylglutaric aciduria is not typically seen in this condition.

+5. Organic acidemia (unspecified): Consistent with dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. Additional testing is needed to identify the specific type of organic acidemia.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Matches abnormal copper metabolism (increased urinary copper, decreased circulating copper and ceruloplasmin), elevated transaminases, and potential for severe complications leading to death in childhood.

+2. Porphyria: Consistent with abnormal circulating porphyrin and amino acid concentrations. Key symptoms like photosensitivity, abdominal pain, and neurological issues were not reported.

+3. Hemochromatosis: Aligns with decreased circulating iron concentration. Symptoms like fatigue, joint pain, and skin discoloration were not mentioned.

+4. Nutritional deficiency: Carious teeth and obesity could be related to dietary issues or malabsorption disorders, which can also affect metal metabolism. Specific deficiencies were not provided.

+5. Metabolic disorder: The combination of symptoms involving multiple organ systems and metabolic pathways suggests an underlying metabolic disorder. Further testing is needed to identify the specific condition.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potentially leading to developmental abnormalities and early death.

+2. Congenital malformation: Abnormality of prenatal development or birth, which could result in neonatal or infant death.

+3. Chromosomal abnormality: Potential genetic cause of developmental abnormalities and increased risk of neonatal or infant death.

+4. Intrauterine infection: Infections acquired during pregnancy can cause congenital abnormalities and potentially lead to neonatal or infant death.

+5. Placental insufficiency: Inadequate placental function can result in developmental abnormalities and increased risk of neonatal or infant death.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, death in infancy/childhood. Key symptom not reported: liver disease, kidney problems.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures, neurological problems.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Key symptom not reported: failure to thrive, chronic diarrhea.

+4. Leukocyte adhesion deficiency (LAD): Consistent with recurrent viral infections. Key symptoms not reported: delayed separation of the umbilical cord, skin infections.

+5. Organic acidemia: Consistent with death in infancy/childhood, hypertyrosinemia, hyperphenylalaninemia. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with abnormal circulating glycine concentration and aminoaciduria.

+2. Methylmalonic acidemia: Consistent with elevated urinary carboxylic acid and aminoaciduria. Key symptom not reported: metabolic acidosis.

+3. Propionic acidemia: Consistent with elevated urinary carboxylic acid and aminoaciduria. Key symptom not reported: metabolic acidosis.

+4. Carnitine deficiency: Consistent with abnormal circulating carnitine concentration. Key symptoms not reported: muscle weakness, cardiomyopathy, hypoglycemia.

+5. Phenylketonuria: Consistent with aminoaciduria. Key symptom not reported: elevated phenylalanine levels.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Mitochondrial disorder: Consistent with generalized hypotonia, hepatomegaly, tachypnea, 3-methylglutaconic aciduria, neonatal death, and feeding difficulties. Key symptoms not reported: seizures, lactic acidosis, and developmental delays.

+2. Organic acidemia: Consistent with 3-methylglutaconic aciduria. Key symptoms not reported: metabolic acidosis, vomiting, lethargy, and developmental delays.

+3. Glycogen storage disease: Consistent with hepatomegaly and hypotonia. Key symptoms not reported: muscle weakness, hypoglycemia, and growth retardation.

+4. Congenital muscular dystrophy: Consistent with generalized hypotonia and feeding difficulties. Key symptoms not reported: muscle weakness, respiratory difficulties, and delayed motor milestones.

+5. Rare congenital metabolic disorder: Consistent with the combination of generalized hypotonia, hepatomegaly, tachypnea, 3-methylglutaconic aciduria, neonatal death, and feeding difficulties. Specific symptoms may vary depending on the disorder.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Urea cycle disorder: Consistent with hyperammonemia, respiratory alkalosis, lethargy, developmental delays, and potential neonatal/childhood death. May also explain elevated plasma citrulline and liver dysfunction.

+2. Organic acidemia: Consistent with hypoglycemia, lethargy, developmental delays, and potential neonatal/childhood death. May also contribute to metabolic abnormalities and liver dysfunction.

+3. Mitochondrial disorder: Consistent with multi-system involvement, developmental delays, hypoglycemia, lethargy, and potential neonatal/childhood death. May also explain obesity and hyperhidrosis.

+4. Congenital infection: Consistent with developmental delays, abnormality of prenatal development or birth, and potential neonatal/childhood death. However, does not explain metabolic or liver abnormalities.

+5. Genetic syndrome: Consistent with developmental delays, obesity, hyperhidrosis, and potential neonatal/childhood death. May also contribute to multi-system involvement and metabolic abnormalities, depending on the specific syndrome.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric aciduria type 1 (GA1): Consistent with macrocephaly, seizures, hypotonia, and metabolic abnormality (glutaric aciduria). May not explain visual evoked potential abnormalities or athetosis.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with macrocephaly, seizures, hypotonia, and visual evoked potential abnormalities. May not explain glutaric aciduria.

+3. Zellweger syndrome: Consistent with macrocephaly, seizures, hypotonia, and neurological deterioration. May not explain glutaric aciduria or visual evoked potential abnormalities.

+4. Aicardi-Goutières syndrome: Consistent with macrocephaly, seizures, irritability, and neurological deterioration. May not explain glutaric aciduria or athetosis.

+5. Severe brain malformation or injury: Consistent with macrocephaly, seizures, hypotonia, and visual evoked potential abnormalities. May not explain glutaric aciduria or athetosis.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia type I: Matches hypertyrosinemia, elevated urinary delta-aminolevulinic acid, and delayed speech/language development. May also explain death in childhood if untreated.

+2. Succinic semialdehyde dehydrogenase deficiency: Consistent with delayed speech/language development and 4-hydroxyphenylpyruvic aciduria. Does not typically involve hypertyrosinemia or elevated urinary delta-aminolevulinic acid.

+3. Hawkinsinuria: Matches 4-hydroxyphenylpyruvic aciduria, but does not typically cause delayed speech/language development, hypertyrosinemia, or elevated urinary delta-aminolevulinic acid.

+4. Phenylketonuria (PKU): Consistent with abnormal circulating phenylalanine concentration and delayed speech/language development. Does not typically involve the other reported biochemical abnormalities.

+5. Lesch-Nyhan syndrome: Matches delayed speech/language development, but does not typically involve the reported biochemical abnormalities.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, elevated urinary carboxylic acid. May not explain obesity.

+2. Tyrosinemia: Consistent with hypertyrosinemia, elevated urinary carboxylic acid. May not explain obesity.

+3. Congenital malformation or chromosomal abnormality: Consistent with abnormality of prenatal development or birth, death in infancy/childhood. May not fully explain metabolic abnormalities.

+4. Mitochondrial disorder: Consistent with abnormality of prenatal development or birth, death in infancy/childhood, metabolic derangements. Specific symptoms may vary.

+5. Other inborn error of metabolism: Consistent with metabolic abnormalities, abnormal prenatal development, early mortality. Specific condition uncertain without further testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with intellectual disability, seizures, hyperphenylalaninemia, and early death. Key symptom not reported: fair skin and hair pigmentation.

+2. Tyrosinemia: Consistent with intellectual disability, seizures, hypertyrosinemia, elevated urinary carboxylic acid, and early death. Key symptom not reported: liver dysfunction or failure.

+3. Lesch-Nyhan syndrome: Consistent with hyperactivity, intellectual disability, seizures, and self-mutilating behavior (not reported).

+4. Mitochondrial disorder: Consistent with intellectual disability, seizures, short stature, and multi-system involvement. Key symptoms not reported: muscle weakness, vision or hearing problems, and specific metabolic abnormalities.

+5. Chromosomal abnormality (e.g., Down syndrome): Consistent with intellectual disability and short stature. Key symptoms not reported: characteristic facial features and congenital malformations.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, metabolic acidosis, hyperammonemia, vomiting, and potentially the neurological symptoms (seizures, hypotonia, and death in infancy). Key symptoms not reported: developmental delays, failure to thrive, and recurrent episodes of metabolic decompensation.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, vomiting, thrombocytopenia, leukopenia, and potentially the neurological symptoms. Key symptoms not reported: developmental delays, protein intolerance, and recurrent episodes of metabolic decompensation.

+3. Isovaleric acidemia: Consistent with metabolic acidosis, vomiting, and potentially the neurological symptoms. Key symptoms not reported: distinctive sweaty feet odor, protein intolerance, and recurrent episodes of metabolic decompensation.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, seizures, hypotonia, and multi-organ involvement. Key symptoms not reported: specific neurological or muscular manifestations depending on the type of mitochondrial disorder.

+5. Organic acidemia (unspecified): Consistent with metabolic acidosis, hyperammonemia, vomiting, and potentially the neurological symptoms. Key symptoms not reported: specific metabolic abnormalities and clinical features depending on the type of organic acidemia.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potentially leading to developmental abnormalities and neonatal/infant death.

+2. Congenital malformation: Abnormality of prenatal development or birth, which could result in neonatal/infant death.

+3. Chromosomal abnormality: Abnormality of prenatal development or birth, potentially causing developmental issues and increased risk of neonatal/infant death.

+4. Intrauterine infection: Abnormality of prenatal development or birth, which could be caused by infections acquired during pregnancy, leading to congenital abnormalities and neonatal death.

+5. Placental insufficiency: Abnormality of prenatal development or birth, potentially due to inadequate placental function, resulting in developmental abnormalities and increased risk of neonatal death.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with methylmalonic aciduria, metabolic acidosis, hyperammonemia, and vomiting. May not present with death in infancy if treated promptly.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, and vomiting. May not present with methylmalonic aciduria.

+3. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, and vomiting. May not present with methylmalonic aciduria.

+4. Neonatal liver disease: Consistent with metabolic acidosis, hyperammonemia, and vomiting. May not present with methylmalonic aciduria.

+5. Sepsis: Consistent with metabolic acidosis and vomiting. May not present with hyperammonemia or methylmalonic aciduria.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, seizures, cerebral edema, oroticaciduria, and neonatal death.
+2. Ornithine transcarbamylase deficiency (OTC deficiency): A specific urea cycle disorder that can present with all the reported symptoms.
+3. Carbamoyl phosphate synthetase I deficiency (CPS1 deficiency): Another urea cycle disorder that matches the symptom profile.
+4. Citrullinemia: A urea cycle disorder characterized by hyperammonemia, seizures, and cerebral edema. Oroticaciduria may or may not be present.
+5. Organic acidemia: While not as likely as urea cycle disorders, some organic acidemias can cause hyperammonemia, seizures, and cerebral edema in neonates.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Leigh syndrome: Consistent with seizures, generalized hypotonia, growth delay, death in infancy, fasciculations, and elevated urinary carboxylic acid. Alopecia is not a typical symptom.

+2. Mitochondrial disorders: Consistent with seizures, generalized hypotonia, growth delay, and elevated urinary carboxylic acid. Death in infancy is possible in severe cases. Alopecia and fasciculations are less common.

+3. Menkes disease: Consistent with seizures, generalized hypotonia, growth delay, alopecia, and death in infancy. Elevated urinary carboxylic acid is not a typical symptom.

+4. Spinal muscular atrophy (SMA): Consistent with generalized hypotonia and fasciculations. Seizures, growth delay, death in infancy, alopecia, and elevated urinary carboxylic acid are not common features.

+5. Leukodystrophies: Consistent with seizures, generalized hypotonia, and growth delay. Death in infancy, alopecia, fasciculations, and elevated urinary carboxylic acid are not typical symptoms.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Hypertyrosinemia, hyperphenylalaninemia, obesity, and early death are consistent with this inherited metabolic disorder. Key symptoms not reported: liver disease, kidney problems, neurological issues.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia and intellectual disability (not reported) are characteristic of this disorder. However, it does not fully explain the obesity, high cholesterol, or high tyrosine levels.

+3. Familial hypercholesterolemia: Obesity and hypercholesterolemia are consistent with this genetic disorder. Key symptoms not reported: premature cardiovascular disease, xanthomas (cholesterol deposits).

+4. Lysosomal storage disorder: The combination of obesity, high cholesterol, and metabolic abnormalities could potentially fit certain lysosomal storage disorders. Key symptoms not reported: organomegaly, skeletal abnormalities, neurological deficits.

+5. Multiple endocrine neoplasia (MEN) syndrome: Obesity and metabolic abnormalities could be seen in some MEN syndromes. Key symptoms not reported: endocrine tumors, specific hormone imbalances.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Hypertyrosinemia, neonatal death, severe short stature. Key symptoms not reported: liver dysfunction, neurological problems.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia, severe short stature, neonatal death. Key symptoms not reported: developmental delays, seizures.

+3. Congenital adrenal hyperplasia (CAH): Hypospadias, severe short stature. Key symptoms not reported: virilization, electrolyte imbalances.

+4. Chromosomal abnormality (e.g., trisomy 13, 18): Severe short stature, hypospadias, neonatal death. Key symptoms not reported: specific dysmorphic features, congenital anomalies.

+5. Prematurity complications (e.g., necrotizing enterocolitis, intraventricular hemorrhage): Premature birth, neonatal death. Key symptoms not fully explained: metabolic abnormalities, hypospadias, severe short stature.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with microcephaly, low-set ears, wide nasal bridge, strabismus, syndactyly, developmental delays, intellectual disability, short stature, and elevated 7/8-dehydrocholesterol levels. Key symptom not reported: photosensitivity.

+2. Trisomy 18 (Edwards syndrome): Consistent with microcephaly, low-set ears, wide nasal bridge, strabismus, syndactyly, intellectual disability, severe short stature, and potential for neonatal/infant/childhood death. Key symptoms not reported: clenched fists, rocker-bottom feet, and heart defects.

+3. Holoprosencephaly: Consistent with microcephaly, developmental delays, intellectual disability, and motor delays. Key symptoms not reported: cyclopia (single eye), cleft lip/palate, and seizures.

+4. Congenital disorders of glycosylation (CDG): Consistent with developmental delays, intellectual disability, and some physical malformations. Key symptoms not reported: hypoglycemia, protein-losing enteropathy, and coagulopathy.

+5. Fetal alcohol spectrum disorder (FASD): Consistent with microcephaly, developmental delays, intellectual disability, and short stature. Key symptoms not reported: distinctive facial features (smooth philtrum, thin upper lip) and behavioral/social issues.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with ataxia, opisthotonus, athetosis, progressive neurologic deterioration, glutaric aciduria, elevated circulating glutaric acid concentration, decreased plasma free carnitine, and abnormal circulating acylcarnitine concentration. Key symptoms not reported: macrocephaly (enlarged head), hypotonia (low muscle tone).

+2. Maple syrup urine disease (MSUD): Consistent with ataxia, progressive neurologic deterioration, and abnormal circulating acylcarnitine concentration. Key symptoms not reported: maple syrup odor in urine, lethargy, and vomiting.

+3. Organic acidemia: Consistent with ataxia, progressive neurologic deterioration, glutaric aciduria, and abnormal circulating acylcarnitine concentration. Key symptoms not reported: vomiting, lethargy, and failure to thrive.

+4. Meningitis: Consistent with fever, opisthotonus, and dehydration. Key symptoms not reported: headache, photophobia (light sensitivity), and neck stiffness.

+5. Encephalitis: Consistent with fever, ataxia, and progressive neurologic deterioration. Key symptoms not reported: headache, altered mental status, and seizures.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and developmental delays. Key symptom not reported: intellectual disability if untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia, developmental delays, and potential liver involvement. Key symptoms not reported: liver dysfunction, renal tubular dysfunction.

+3. Congenital muscular dystrophy: Consistent with generalized hypotonia, motor delay, and prenatal abnormalities. Key symptoms not reported: progressive muscle weakness, respiratory complications.

+4. Chromosomal abnormality or genetic syndrome: Consistent with the broad range of symptoms, including developmental delays, hypotonia, and congenital malformations. Specific syndrome would depend on additional clinical and genetic findings.

+5. Congenital malformation or birth defect: Consistent with abnormality of prenatal development or birth, motor delay, and hip dysplasia. Specific diagnosis would depend on the type and pattern of malformations.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn Error of Metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, seizures, and potential neurological symptoms. Key symptoms not reported: specific metabolic abnormalities or organ involvement.

+2. Chromosomal Abnormality or Genetic Syndrome: Consistent with retrognathia, abnormality of prenatal development, generalized hypotonia, and potential neurological symptoms. Key symptoms not reported: specific dysmorphic features or associated anomalies.

+3. Severe Brain Malformation or Neurodegenerative Disorder: Consistent with seizures, generalized hypotonia, apnea, opisthotonus, and potential neurological symptoms. Key symptoms not reported: specific neurological deficits or developmental delays.

+4. Congenital Myopathy or Muscular Dystrophy: Consistent with generalized hypotonia and potential respiratory involvement (apnea). Key symptoms not reported: specific muscle weakness or involvement patterns.

+5. Severe Perinatal Asphyxia or Hypoxic-Ischemic Encephalopathy: Consistent with seizures, generalized hypotonia, apnea, and potential neurological symptoms. Key symptoms not reported: specific details of the perinatal event or brain injury.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia: Matches hypertyrosinemia, elevated alkaline phosphatase and alpha-fetoprotein, and potential for neonatal/infant death. Does not explain neurodevelopmental symptoms.

+2. Maple syrup urine disease (MSUD): Consistent with abnormal circulating aspartate family amino acids and potential for neonatal death. Does not fully account for other symptoms.

+3. Phenylketonuria (PKU): Fits hyperphenylalaninemia and intellectual disability. Does not explain self-mutilation, elevated alkaline phosphatase, or neonatal/infant death.

+4. Peroxisomal disorders (e.g., Zellweger syndrome): Can cause neurodevelopmental symptoms, seizures, and elevated alkaline phosphatase and alpha-fetoprotein. Self-mutilation and specific amino acid abnormalities are not typical.

+5. Lesch-Nyhan syndrome: Matches intellectual disability, self-mutilation, and potential for elevated circulating alkaline phosphatase. Does not explain amino acid abnormalities or neonatal/infant death.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with hypergalactosemia, vomiting, increased total bilirubin, and potentially death in infancy if left untreated.
+2. Inborn error of metabolism: Consistent with vomiting, increased total bilirubin, and potentially hypergalactosemia, depending on the specific enzyme deficiency. Death in infancy may occur in severe cases.
+3. Biliary atresia: Consistent with increased total bilirubin and vomiting, but does not explain hypergalactosemia. Neonatal death can occur if left untreated.
+4. Neonatal hepatitis: Consistent with increased total bilirubin and vomiting, but does not explain hypergalactosemia or death in infancy.
+5. Congenital liver disease: Consistent with increased total bilirubin and potentially vomiting, but does not explain hypergalactosemia or death in infancy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and abnormal tyrosine levels. Key symptom not reported: intellectual disability if untreated.

+2. Maple syrup urine disease: A type of amino acid disorder that could explain the abnormal amino acid levels and potential neonatal complications. Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+3. Congenital malformations/genetic disorders: Consistent with abnormality of prenatal development and potential neonatal death. Additional information needed to specify the condition.

+4. Chromosomal abnormalities: Could potentially cause the reported symptoms, but more details are required for a specific diagnosis.

+5. Organic acidemias: A group of metabolic disorders that could lead to abnormal amino acid levels and potential neonatal complications. Key symptoms not reported: vomiting, lethargy, acidosis.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Carnitine deficiency disorders: Consistent with abnormal circulating carnitine concentration and early death. Key symptom not reported: metabolic crises, hypoglycemia, cardiomyopathy.

+2. Fatty acid oxidation disorders: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: hypoglycemia, metabolic crises, liver dysfunction.

+3. Organic acidemias: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: metabolic crises, developmental delays, seizures.

+4. Lysosomal storage diseases: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: organomegaly, skeletal abnormalities, neurological deficits.

+5. Congenital heart defects: Consistent with early death. Key symptoms not reported: cyanosis, heart murmurs, respiratory distress.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and intellectual disability. May not explain all symptoms, such as prenatal abnormalities or early death.

+2. Tyrosinemia: Consistent with hypertyrosinemia, intellectual disability, and potential for liver dysfunction leading to early death. May not explain prenatal abnormalities.

+3. Chromosomal abnormality or genetic syndrome: Could account for prenatal/birth abnormalities, intellectual disability, and potential for early death. Specific syndrome would depend on additional clinical and genetic testing.

+4. Congenital malformation or birth defect: Consistent with abnormality of prenatal development or birth, and could potentially lead to early death. May not explain metabolic abnormalities or intellectual disability.

+5. Severe perinatal infection or injury: Could potentially cause prenatal/birth abnormalities, intellectual disability, and early death. May not explain metabolic abnormalities.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz Syndrome (SLOS): Consistent with congenital anomalies, developmental delays, intellectual disability, hypotonia, and elevated 7-dehydrocholesterol and 8-dehydrocholesterol levels. Key symptoms not reported: Photosensitive rash, failure to thrive.

+2. Congenital Disorders of Glycosylation (CDG): Consistent with developmental delays, hypotonia, and metabolic abnormalities. Key symptoms not reported: Coagulopathy, protein-losing enteropathy.

+3. Peroxisomal Disorders (e.g., Zellweger Syndrome, Rhizomelic Chondrodysplasia Punctata): Consistent with congenital anomalies, developmental delays, hypotonia, and metabolic abnormalities. Key symptoms not reported: Hepatomegaly, calcific stippling of epiphyses.

+4. Chromosomal Abnormalities (e.g., Trisomies, Microdeletion Syndromes): Consistent with congenital anomalies, developmental delays, and intellectual disability. Key symptoms not reported: Specific dysmorphic features associated with the chromosomal abnormality.

+5. Mitochondrial Disorders: Consistent with developmental delays, hypotonia, lethargy, and metabolic abnormalities. Key symptoms not reported: Lactic acidosis, myopathy, seizures.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Consistent with strabismus, hyporeflexia, generalized hypotonia, cerebral atrophy, and abnormal circulating aspartate family amino acid concentration. May not explain obesity or death in infancy.

+2. Congenital muscular dystrophy: Consistent with strabismus, hyporeflexia, generalized hypotonia, and potentially death in infancy. May not explain cerebral atrophy, obesity, or abnormal amino acid levels.

+3. Mitochondrial disorder: Consistent with hyporeflexia, generalized hypotonia, cerebral atrophy, and potentially death in infancy. May not explain strabismus, obesity, or abnormal amino acid levels.

+4. Prader-Willi syndrome: Consistent with obesity, hypotonia, and potentially developmental delays. May not explain strabismus, hyporeflexia, cerebral atrophy, or abnormal amino acid levels.

+5. Congenital infection: Consistent with fever and potentially cerebral atrophy. May not explain other neurological symptoms, obesity, or abnormal amino acid levels.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Congenital heart defect: Consistent with coarctation of the aorta and potential early mortality. Key symptoms like cyanosis or heart murmurs not reported.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential complications leading to early mortality. Key symptoms like developmental delays or neurological issues not reported.

+3. Tyrosinemia: Consistent with hypertyrosinemia and potential early mortality. Key symptoms like liver dysfunction or neurological issues not reported.

+4. Severe infection: Consistent with fever and pneumonia, which could contribute to early mortality, especially in infants or those with underlying conditions. Key symptoms like specific infection site or causative organism not reported.

+5. Genetic or chromosomal disorder: Consistent with multiple congenital abnormalities and potential early mortality. Key symptoms or specific disorder not reported.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with hyperhomocystinemia, hypermethioninemia, and aminoaciduria. May also present with developmental delays and other complications.

+2. Methylmalonic acidemia: Consistent with aminoaciduria and potential neonatal complications. Elevated methylmalonic acid levels (not reported) are a key symptom.

+3. Maple syrup urine disease: Consistent with aminoaciduria and potential neonatal complications. Characteristic maple syrup odor (not reported) is a key symptom.

+4. Trisomy 13 (Patau syndrome): Consistent with abnormalities of prenatal development or birth and potential neonatal/childhood death. Other characteristic features (e.g., congenital malformations) not reported.

+5. Trisomy 18 (Edwards syndrome): Consistent with abnormalities of prenatal development or birth and potential neonatal/childhood death. Other characteristic features (e.g., congenital malformations) not reported.",Hereditary metabolic disorders
[],"+1. Lesch-Nyhan syndrome: Consistent with ataxia, hypotonia, and abnormal pyrimidine metabolism. Key symptom not reported: self-mutilating behavior.

+2. Hereditary ataxia: Consistent with ataxia and hypotonia. Key symptoms not reported: specific genetic or clinical features of the various ataxia subtypes.

+3. Mitochondrial disorder: Consistent with ataxia, hypotonia, and potential metabolic disturbances. Key symptoms not reported: specific features of the mitochondrial disorder subtype.

+4. Pyrimidine metabolic disorder (e.g., DPD deficiency, orotic aciduria): Consistent with abnormal pyrimidine concentration and uraciluria. Key symptoms not reported: specific features of the disorder subtype.

+5. Unspecified metabolic disorder: Consistent with ataxia, hypotonia, and abnormal metabolic findings. Key symptoms not reported: specific metabolic pathway or enzyme deficiency.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia and potential for early death if untreated. Key symptoms not reported: liver disease, neurological problems.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures.

+3. Maple syrup urine disease (MSUD): Consistent with potential for early death if severe. Key symptoms not reported: elevated levels of leucine, isoleucine, and valine.

+4. Homocystinuria: Consistent with potential for early death if untreated. Key symptoms not reported: developmental delays, intellectual disability.

+5. Urea cycle disorders: Consistent with potential for hyperammonemia and early death if untreated. Key symptoms not reported: vomiting, lethargy, seizures.",Hereditary metabolic disorders
[],"+1. Orotic aciduria: Consistent with abnormal circulating pyrimidine concentration, uraciluria, and potentially contributing to respiratory insufficiency and neonatal death. Key symptom not reported: crystalline deposits in body fluids.

+2. Hereditary orotic aciduria: Consistent with abnormal circulating pyrimidine concentration, uraciluria, and potentially contributing to respiratory insufficiency and neonatal death. Key symptom not reported: developmental delay.

+3. Primary ciliary dyskinesia: Consistent with respiratory insufficiency and potentially contributing to neonatal death. Key symptoms not reported: chronic respiratory infections, situs inversus, male infertility.

+4. Congenital diaphragmatic hernia: Consistent with respiratory insufficiency and potentially contributing to neonatal death. Key symptoms not reported: bowel herniation into the chest cavity, pulmonary hypoplasia.

+5. Mitochondrial respiratory chain disorder: Consistent with respiratory insufficiency and potentially contributing to neonatal death. Key symptoms not reported: lactic acidosis, seizures, muscle weakness.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Biliary atresia: Consistent with ascites, hypoalbuminemia, hypoproteinemia, elevated alkaline phosphatase and alpha-fetoprotein levels. May not explain all symptoms like hypertyrosinemia or aminoaciduria.

+2. Tyrosinemia: Matches hypertyrosinemia, aminoaciduria, and potential liver involvement. May not account for ascites or hematological abnormalities.

+3. Hemolytic anemia: Aligns with pallor, anemia, and thrombocytosis. Does not explain liver dysfunction or metabolic abnormalities.

+4. Hepatoblastoma (liver cancer): Could explain liver dysfunction, ascites, and elevated alpha-fetoprotein. May not fit with metabolic or hematological findings.

+5. Alpha-1 antitrypsin deficiency: A genetic disorder that can cause liver disease and potentially explain some liver-related symptoms. May not account for metabolic or hematological abnormalities.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease (MSUD): Consistent with seizures, motor delay, and abnormal circulating aspartate family amino acid concentration. Classic symptom of maple syrup odor in urine may not be reported.

+2. Phenylketonuria (PKU): Consistent with seizures, motor delay, and abnormal circulating aspartate family amino acid concentration. Lack of reported hypopigmentation or eczema.

+3. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with seizures, motor delay, and potential for early death. Specific symptoms like vision loss or peripheral neuropathy may not be reported.

+4. Chromosomal abnormality (e.g., trisomy 18, trisomy 13): Consistent with seizures, motor delay, and potential for early death. Specific physical features or congenital anomalies may not be reported.

+5. Congenital brain malformation (e.g., lissencephaly, holoprosencephaly): Consistent with seizures and motor delay. Lack of reported specific physical features or associated anomalies.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, gastrointestinal inflammation, recurrent viral infections, and potentially fatal in infancy/childhood. May not explain body odor.

+2. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with abnormal circulating metabolite levels (carnitine), gastrointestinal symptoms, body odor, and potentially fatal in infancy/childhood. May not fully explain recurrent viral infections.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potentially fatal in infancy/childhood. Does not explain gastrointestinal symptoms or abnormal metabolite levels.

+4. Inflammatory bowel disease (IBD): Consistent with gastrointestinal inflammation, diarrhea, abdominal pain, and potentially fatal in childhood/adolescence. Does not explain abnormal metabolite levels or recurrent viral infections.

+5. Congenital gastrointestinal disorder: Consistent with gastrointestinal symptoms (vomiting, diarrhea, abdominal pain, inflammation) and potentially fatal in infancy/childhood. May not explain abnormal metabolite levels or recurrent viral infections.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, intellectual disability. Key symptom not reported: fair skin, light hair, and blue eyes (in some cases).

+2. Tyrosinemia: Hypertyrosinemia, intellectual disability, elevated urinary carboxylic acid. Key symptoms not reported: liver disease, kidney disease, rickets.

+3. Inborn error of metabolism (organic acidemia): Intellectual disability, obesity, elevated urinary carboxylic acid. Key symptoms not reported: specific metabolic abnormalities depending on the disorder.

+4. Genetic syndrome (e.g., Prader-Willi, Bardet-Biedl): Intellectual disability, obesity, hypertension. Key symptoms not reported: specific dysmorphic features or other manifestations of the syndrome.

+5. Hypertensive encephalopathy: Hypertension, intellectual disability. Key symptoms not reported: severe headache, vision changes, seizures.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Hyperalaninemia, abnormal carnitine levels, prenatal abnormalities, and early death are consistent with IEMs. Key symptoms like metabolic acidosis or specific biochemical abnormalities may not be reported.

+2. Chromosomal abnormality or genetic syndrome: Prenatal abnormalities, small for gestational age, and developmental delays/death could be explained by trisomies or other genetic syndromes. Specific dysmorphic features or congenital anomalies may not be mentioned.

+3. Congenital infection (TORCH): Prenatal abnormalities, growth restriction, and hearing impairment could result from intrauterine infections like cytomegalovirus or rubella. Specific clinical findings like rash or hepatosplenomegaly may not be reported.

+4. Perinatal asphyxia or hypoxic-ischemic encephalopathy: Neonatal death, developmental delays, and hearing impairment could be due to severe birth asphyxia. Details about the perinatal course or neuroimaging findings may not be provided.

+5. Congenital malformation or structural abnormality: Prenatal abnormalities and early death could be caused by major congenital malformations of vital organs like the heart, brain, or kidneys. Specific details about the malformations may not be included.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with lethargy, drowsiness, and abnormal circulating ornithine concentration. Key symptom not reported: Hyperammonemia.

+2. Mitochondrial disorder: Consistent with lethargy, drowsiness, sleep abnormality, and potential metabolic abnormalities. Key symptoms not reported: Muscle weakness, seizures, developmental delays.

+3. Organic acidemia: Consistent with lethargy, drowsiness, and potential metabolic abnormalities (oroticaciduria). Key symptoms not reported: Vomiting, acidosis, failure to thrive.

+4. Fatty acid oxidation disorder: Consistent with lethargy, drowsiness, and potential metabolic abnormalities. Key symptoms not reported: Hypoglycemia, liver dysfunction, cardiomyopathy.

+5. Leigh syndrome: Consistent with lethargy, drowsiness, sleep abnormality. Key symptoms not reported: Ataxia, ophthalmoplegia, respiratory distress.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with ataxia, dystonia, abnormal cerebral morphology, glutaric aciduria, decreased plasma free carnitine, and potential death in childhood. May not fully explain abnormal myelination.

+2. Leukodystrophy (e.g., metachromatic leukodystrophy, Krabbe disease): Consistent with ataxia, dystonia, abnormal cerebral morphology, and abnormal myelination. Does not typically involve glutaric aciduria or decreased carnitine levels.

+3. Mitochondrial disorder (e.g., Leigh syndrome, MELAS): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential death in childhood. Typically does not involve glutaric aciduria or decreased carnitine levels.

+4. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential metabolic abnormalities. May not fully explain abnormal myelination or decreased carnitine levels.

+5. Neurodegenerative disorder (e.g., infantile neuroaxonal dystrophy): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential death in childhood. Typically does not involve specific metabolic abnormalities like glutaric aciduria or decreased carnitine levels.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, a key symptom of this genetic disorder that impairs phenylalanine metabolism. Neonatal death can occur if left untreated.

+2. Maple syrup urine disease: An inborn error of metabolism that can cause hyperphenylalaninemia, along with other metabolic abnormalities. Severe cases can lead to neonatal death.

+3. Organic acidemias: A group of metabolic disorders that can cause hyperphenylalaninemia and other metabolic imbalances, potentially leading to neonatal death in severe cases.

+4. Congenital malformations: Severe congenital abnormalities or malformations could potentially explain neonatal death, although the hyperphenylalaninemia symptom suggests a metabolic disorder is more likely.

+5. Chromosomal abnormalities: Certain chromosomal disorders, such as trisomies or deletions, can be associated with neonatal death, but the hyperphenylalaninemia symptom is not typically seen in these conditions.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with encephalopathy, hypotonia, cardiomyopathy, hypoglycemia, vomiting, abnormal amino acid and carnitine levels. May not explain hepatomegaly or elevated transaminases.

+2. Mitochondrial disorder: Matches encephalopathy, cardiomyopathy, hypoglycemia, anemia, and multi-system involvement. May not account for hepatomegaly or elevated transaminases.

+3. Lysosomal storage disorder: Consistent with hepatomegaly, neurological symptoms, and metabolic abnormalities. May not explain cardiomyopathy or hypoglycemia.

+4. Acute liver failure or inborn error of metabolism affecting the liver: Explains hepatomegaly, elevated transaminases, vomiting, and metabolic disturbances. May not account for cardiomyopathy or neurological symptoms.

+5. Genetic syndrome or chromosomal abnormality: Could potentially explain the multi-system involvement and severe presentation. Specific symptoms may vary depending on the underlying condition.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Joubert syndrome: Consistent with ataxia, nystagmus, hypotonia, motor delay, cerebellar agenesis or atrophy, and developmental delays. Key symptoms not reported: polydactyly (extra digits), breathing abnormalities.

+2. Pontocerebellar hypoplasia: Consistent with ataxia, nystagmus, hypotonia, motor delay, cerebellar atrophy or agenesis, and developmental delays. Key symptoms not reported: microcephaly (small head size), seizures.

+3. Leukodystrophy (e.g., Pelizaeus-Merzbacher disease): Consistent with ataxia, hypotonia, motor delay, encephalopathy, and developmental delays. Key symptoms not reported: visual impairment, hearing loss.

+4. Ataxia-telangiectasia: Consistent with ataxia, nystagmus, and cerebellar atrophy. Key symptoms not reported: telangiectasias (dilated blood vessels), immunodeficiency.

+5. Congenital disorder of glycosylation: Consistent with ataxia, hypotonia, motor delay, encephalopathy, and developmental delays. Key symptoms not reported: dysmorphic features, coagulopathy (bleeding disorders).",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Cystathionine beta-synthase deficiency: Matches hyperhomocystinemia, hypermethioninemia, aminoaciduria, intellectual disability, ectopia lentis. May not explain myopia or delayed speech/language development.

+2. Homocystinuria: Consistent with hyperhomocystinemia, intellectual disability, ectopia lentis. Does not account for hypermethioninemia, aminoaciduria, or myopia.

+3. Leukodystrophy: Fits intellectual disability, delayed speech/language development, potential early death. Does not explain metabolic or eye symptoms.

+4. Marfan syndrome: Matches myopia and ectopia lentis. Does not explain metabolic abnormalities, intellectual disability, or early death.

+5. Aminoaciduria: Consistent with aminoaciduria. Does not account for other symptoms.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, lethargy, and potential early death. Key symptom not reported: vomiting.

+2. Mitochondrial disorder: Consistent with seizures, ataxia, lethargy, metabolic acidosis, gastrointestinal symptoms, and potential early death. Key symptom not reported: muscle weakness.

+3. Leukodystrophy: Consistent with seizures, ataxia, lethargy, hyperreflexia, and potential early death. Key symptom not reported: progressive cognitive decline.

+4. Organic acidemia: Consistent with metabolic acidosis, lethargy, and potential early death. Key symptoms not reported: vomiting, failure to thrive.

+5. Pyridoxine (vitamin B6) dependency: Consistent with seizures, lethargy, and metabolic acidosis. Key symptoms not reported: developmental delay, irritability.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Microcephaly, intellectual disability, syndactyly, hypotonia, ataxia, hyperreflexia, failure to thrive, hypocholesterolemia, elevated 8-dehydrocholesterol. Key symptoms not reported: cleft palate, genital abnormalities.

+2. Zellweger spectrum disorders (ZSDs): Microcephaly, intellectual disability, hypotonia, ataxia, hyperreflexia, failure to thrive, feeding difficulties, fatigue. Key symptoms not reported: cholesterol abnormalities.

+3. Congenital disorders of glycosylation (CDGs): Intellectual disability, hypotonia, failure to thrive, feeding difficulties, fatigue. Key symptoms not reported: cholesterol abnormalities, physical abnormalities.

+4. Mitochondrial disorders: Intellectual disability, hypotonia, ataxia, hyperreflexia, failure to thrive, feeding difficulties, fatigue. Key symptoms not reported: cholesterol abnormalities, physical abnormalities.

+5. Leukodystrophies: Microcephaly, intellectual disability, hypotonia, ataxia, hyperreflexia, failure to thrive, feeding difficulties, fatigue. Key symptoms not reported: cholesterol abnormalities, physical abnormalities.",Hereditary metabolic disorders
['Glycogen storage disease due to glycogen debranching enzyme deficiency'],"+1. Mitochondrial disorder: Consistent with generalized hypotonia, increased lactate, abnormal amino acid levels, and elevated creatine kinase. Key symptom not reported: neurological manifestations (e.g., seizures, developmental delay).

+2. Fatty acid oxidation disorder: Consistent with hypertriglyceridemia, hepatomegaly, and hypotonia. Key symptom not reported: hypoglycemia.

+3. Organic acidemia: Consistent with increased lactate, abnormal amino acid levels, and hypotonia. Key symptom not reported: metabolic acidosis.

+4. Glycogen storage disease: Consistent with hepatomegaly, hypotonia, and elevated creatine kinase. Key symptom not reported: hypoglycemia.

+5. Congenital myopathy: Consistent with generalized hypotonia and elevated creatine kinase. Key symptoms not reported: specific muscle weakness patterns, respiratory involvement.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, abnormal acylcarnitine levels, hypotonia, and potential for early death. Microcephaly and athetosis are less common.

+2. Leigh syndrome: Matches microcephaly, hypotonia, athetosis, cerebral cortical atrophy, and potential for early death. Metabolic abnormalities may or may not be present.

+3. Leukodystrophies (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with microcephaly, hypotonia, athetosis, and neurodegeneration leading to early death. Metabolic abnormalities may or may not be present.

+4. Mitochondrial disorders (e.g., mitochondrial encephalomyopathies): Can present with the reported neurological, muscular, and metabolic abnormalities, including hypotonia, athetosis, and potential for early death.

+5. Cerebral palsy (severe forms): May involve microcephaly, hypotonia, athetosis, and brain abnormalities. However, the metabolic and early mortality aspects are less consistent with the reported symptoms.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Non-ketotic hyperglycinemia (NKH): Consistent with hyperglycinemia, hyperglycinuria, hyperammonemia, and potential death in infancy/childhood. May not exhibit hyperalaninemia or ichthyosis.

+2. Glycine encephalopathy: Consistent with hyperglycinemia, hyperglycinuria, hyperammonemia, and potential death in infancy/childhood. May not exhibit hyperalaninemia, ichthyosis, or elevated urinary carboxylic acid.

+3. Organic acidemia: Consistent with elevated urinary carboxylic acid, hyperammonemia, and potential death in infancy/childhood. May not exhibit hyperglycinemia, hyperglycinuria, or ichthyosis.

+4. Disorder of amino acid metabolism: Consistent with hyperalaninemia, abnormal circulating glutamine and carnitine concentrations, and potential death in infancy/childhood. May not exhibit hyperglycinemia, hyperglycinuria, or ichthyosis.

+5. Fatty acid oxidation disorder: Consistent with abnormal circulating carnitine concentrations, hyperammonemia, and potential death in infancy/childhood. May not exhibit hyperglycinemia, hyperglycinuria, hyperalaninemia, or ichthyosis.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Zellweger syndrome: Consistent with intellectual disability, motor delay, abnormal facial shape, abnormal calvaria morphology, abnormal circulating monocarboxylic acid concentration, and elevated urinary carboxylic acid. Death in childhood is common in severe cases.

+2. Glutaric aciduria type 1: Consistent with intellectual disability, motor delay, abnormal circulating monocarboxylic acid concentration, and elevated urinary carboxylic acid. Craniofacial abnormalities are not typical.

+3. Methylmalonic acidemia: Consistent with intellectual disability, motor delay, abnormal circulating monocarboxylic acid concentration, and elevated urinary carboxylic acid. Craniofacial abnormalities are not common.

+4. Craniosynostosis syndromes: Consistent with abnormal facial shape and abnormal calvaria morphology. Metabolic abnormalities are not typical.

+5. Congenital disorders of glycosylation: Consistent with intellectual disability, motor delay, abnormal facial shape, and abnormal circulating monocarboxylic acid concentration. Specific symptoms can vary widely.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with abnormality of galactoside metabolism, hypergalactosemia, liver dysfunction, and potential for severe complications if untreated. Key symptom not reported: Vomiting.

+2. Inborn error of metabolism (amino acid disorder or organic acidemia): Consistent with abnormal circulating amino acid concentrations, liver dysfunction, developmental delays, and potential for severe complications if untreated. Key symptoms not reported may vary depending on the specific disorder.

+3. Genetic syndrome or chromosomal abnormality: Consistent with intellectual disability, developmental delays, and potential for multi-organ involvement. Key symptoms may vary depending on the specific condition.

+4. Liver disease or hepatic failure (etiology unknown): Consistent with hepatic failure, increased bilirubin, prolonged partial thromboplastin time, and potential for severe complications. Key symptoms not reported may depend on the underlying cause.

+5. Prematurity complications: Consistent with premature birth, potential for developmental delays, and increased risk of organ dysfunction. Key symptoms may vary depending on the specific complications.",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, aminoaciduria, elevated plasma citrulline, and potential abnormalities of prenatal development or birth. Key symptoms not reported: neurological symptoms (e.g., lethargy, seizures), respiratory distress.

+2. Organic acidemia: Consistent with hyperammonemia, aminoaciduria, and potential abnormalities of prenatal development or birth. Key symptoms not reported: metabolic acidosis, ketosis, vomiting, lethargy.

+3. Maple syrup urine disease (MSUD): Consistent with abnormal circulating proline concentration, aminoaciduria, and potential neonatal/childhood death. Key symptoms not reported: maple syrup odor, poor feeding, lethargy, seizures.

+4. Aminoacidopathy: Consistent with aminoaciduria and abnormal circulating proline concentration. Key symptoms not reported: specific amino acid imbalances, neurological symptoms, developmental delays.

+5. Congenital disorder of glycosylation: Consistent with abnormalities of prenatal development or birth, and potential neonatal/childhood death. Key symptoms not reported: developmental delays, hypotonia, seizures, coagulopathy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid, hypertyrosinemia, hyperphenylalaninemia, and potentially the immune dysfunction. Key symptoms not reported: specific neurological or developmental manifestations depending on the type of organic acidemia.

+2. Urea cycle disorder: Consistent with hypertyrosinemia, hyperphenylalaninemia, and potentially the immune dysfunction. Key symptoms not reported: specific neurological or developmental manifestations depending on the type of urea cycle disorder.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potentially the metabolic abnormalities as secondary effects. Key symptoms not reported: specific infections or complications related to the type of SCID.

+4. Porphyria: Consistent with abnormal circulating porphyrin concentration and potentially the other metabolic disturbances. Key symptoms not reported: specific neurological, cutaneous, or gastrointestinal manifestations depending on the type of porphyria.

+5. Iron overload disorder (e.g., hereditary hemochromatosis): Consistent with decreased circulating ferritin concentration. Key symptoms not reported: specific organ damage or complications related to iron overload.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with lethargy, hypotonia, tremor, abnormal circulating leucine concentration, elevated urinary carboxylic acid, and body odor. Key symptom not reported: maple syrup odor in urine and cerumen.

+2. Leigh syndrome: Consistent with lethargy, hypotonia, tremor, opisthotonus, drowsiness, and sleep abnormality. Key symptoms not reported: respiratory abnormalities, lactic acidosis, and neuroimaging findings.

+3. Infantile neuroaxonal dystrophy: Consistent with lethargy, hypotonia, tremor, opisthotonus, and death in infancy. Key symptoms not reported: psychomotor regression, seizures, and neuroimaging findings.

+4. Nonketotic hyperglycinemia: Consistent with lethargy, hypotonia, tremor, and opisthotonus. Key symptoms not reported: elevated glycine levels and seizures.

+5. Mitochondrial encephalomyopathy: Consistent with lethargy, hypotonia, tremor, opisthotonus, and drowsiness. Key symptoms not reported: lactic acidosis, seizures, and neuroimaging findings.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism (e.g., phenylketonuria, tyrosinemia): Consistent with hypertyrosinemia, hyperphenylalaninemia, hypotonia, and potential developmental delays. May not explain all symptoms.

+2. Iron deficiency anemia: Consistent with anemia, decreased circulating ferritin and iron concentrations. May not fully account for other symptoms.

+3. Prematurity complications: Consistent with premature birth, hypotonia, and potential metabolic abnormalities. Additional details about gestational age and birth weight would be helpful.

+4. Congenital myopathy: Consistent with generalized hypotonia. Other symptoms may not fit this diagnosis.

+5. Vitamin D deficiency or metabolic disorder: Consistent with abnormality of vitamin D metabolism. More information is needed to determine the primary issue.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration, intellectual disability, delayed speech and language development, motor delay, syndactyly, and abnormal foot morphology. May not explain severe hearing impairment or self-mutilation.

+2. Autism spectrum disorder (ASD): Consistent with intellectual disability, delayed speech and language development, hyperactivity, and self-mutilation. Does not account for metabolic abnormalities or physical abnormalities like syndactyly and abnormal foot morphology.

+3. Fetal alcohol spectrum disorders (FASD): Consistent with intellectual disability, delayed speech and language development, hyperactivity, hypertelorism, and anteverted nares. Does not explain metabolic abnormalities or syndactyly.

+4. Rett syndrome: Consistent with intellectual disability, motor delay, seizures, and self-mutilation. Does not account for metabolic abnormalities, physical abnormalities, or hearing impairment.

+5. Congenital disorders of glycosylation (CDG): Consistent with intellectual disability, developmental delays, seizures, and physical abnormalities. Does not typically involve cholesterol metabolism abnormalities.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, decreased methylmalonyl-CoA mutase activity, and other metabolic abnormalities. Key symptoms not reported: pancreatitis, optic atrophy.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, hyperglycinemia, and other metabolic derangements. Key symptoms not reported: ketosis, pancytopenia.

+3. Urea cycle disorder: Consistent with hyperammonemia, intellectual disability, and metabolic decompensation. Key symptoms not reported: specific biochemical markers for each disorder.

+4. Mitochondrial disorder: Consistent with multi-system involvement, metabolic acidosis, and neurological symptoms. Key symptoms not reported: specific biochemical markers or muscle biopsy findings.

+5. Severe combined immunodeficiency (SCID): Consistent with failure to thrive, recurrent infections (pneumonia), and metabolic abnormalities in some cases. Key symptoms not reported: severe infections, lymphopenia.",Hereditary metabolic disorders
[],"+1. Lesch-Nyhan syndrome: Consistent with ataxia, hypotonia, lethargy, sleep abnormality, abnormal pyrimidine concentration, and uraciluria. May not typically cause death in infancy.

+2. Mitochondrial disorder: Consistent with ataxia, hypotonia, lethargy, and sleep abnormality. Abnormal pyrimidine metabolism and uraciluria are less common features.

+3. Inborn error of pyrimidine metabolism: Consistent with abnormal pyrimidine concentration and uraciluria. Neurological symptoms like ataxia, hypotonia, lethargy, and sleep abnormality may or may not be present, depending on the specific disorder.

+4. Leukodystrophy: Consistent with ataxia, hypotonia, lethargy, and sleep abnormality. Typically does not involve abnormal pyrimidine metabolism or uraciluria.

+5. Neuronal ceroid lipofuscinosis: Consistent with ataxia, hypotonia, lethargy, and sleep abnormality. Typically does not involve abnormal pyrimidine metabolism or uraciluria.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Inborn error of metabolism (IEM): Consistent with abnormality of prenatal development, death in infancy/childhood, hyperammonemia, and abnormal glycine/carnitine levels. Common symptoms of IEMs include developmental delays, seizures, and metabolic crises.

+2. Urea cycle disorder: Consistent with hyperammonemia and abnormal glycine levels. Key symptoms include lethargy, vomiting, and respiratory distress, which were not reported.

+3. Glycine encephalopathy: Consistent with abnormal glycine levels and developmental abnormalities. Patients may also experience seizures and respiratory failure, which were not mentioned.

+4. Mitochondrial disorder: Consistent with abnormal carnitine levels and potential metabolic decompensation. Other symptoms like muscle weakness, seizures, and developmental delays may be present but were not reported.

+5. Fatty acid oxidation defect: Consistent with abnormal carnitine levels and potential metabolic crises. Patients may also experience hypoglycemia, liver dysfunction, and cardiomyopathy, which were not reported.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with seizures, hypotonia, elevated urinary carboxylic acids, and potential death in infancy. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.

+2. Leigh syndrome: Consistent with seizures, hypotonia, and elevated carboxylic acids (lactate). Key symptoms not reported: respiratory difficulties, developmental delays, vision problems.

+3. Nonketotic hyperglycinemia: Consistent with seizures and hypotonia. Key symptoms not reported: apnea, hiccups, elevated glycine levels.

+4. Pyridoxine-dependent epilepsy: Consistent with seizures and hypotonia. Key symptoms not reported: response to pyridoxine (vitamin B6) supplementation.

+5. Mitochondrial encephalomyopathy: Consistent with seizures, hypotonia, and potential elevated lactate (a carboxylic acid). Key symptoms not reported: developmental delays, muscle weakness, vision/hearing problems.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Consistent with decreased enzyme levels, carnitine deficiency, and potential developmental delays or early death. Key symptoms like specific metabolic abnormalities or organ involvement may not be reported.

+2. Chromosomal abnormality or genetic syndrome: Consistent with prenatal/birth abnormalities, developmental delays, and potential early mortality. Specific dysmorphic features or other characteristic symptoms may not be reported.

+3. Congenital malformation or birth defect: Consistent with prenatal/birth abnormalities, developmental delays, and potential early mortality. Specific organ systems affected or associated anomalies may not be reported.

+4. Perinatal complication or injury: Consistent with abnormality of prenatal development or birth, and potential developmental delays or early mortality. Specific details of the complication or injury may not be reported.

+5. Neurodevelopmental disorder: Consistent with delayed speech and language development. Other cognitive, behavioral, or neurological symptoms may not be reported.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, seizures, motor delay, and feeding difficulties. Typical body odor not reported.

+2. Cerebral palsy: Consistent with seizures, spastic diplegia, motor delay, generalized hypotonia, and feeding difficulties. Does not explain metabolic abnormalities.

+3. Mitochondrial disorder: Could potentially explain seizures, motor delays, hypotonia, metabolic acidosis, and dyspnea/apnea. Specific disorder unclear based on symptoms.

+4. Genetic disorder affecting amino acid metabolism: Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, and potentially some neurological symptoms. Specific disorder unclear.

+5. Genetic disorder affecting brain development: Could account for seizures, motor delays, hypotonia, and potentially some metabolic issues. Specific disorder unclear based on symptoms.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Organic acidemia: Consistent with hyperammonemia, hyperglycinemia, hyperalaninemia, increased blood urea nitrogen, elevated circulating creatinine concentration, elevated urinary carboxylic acid. May not explain all symptoms.

+2. Urea cycle disorder: Consistent with hyperammonemia, increased blood urea nitrogen, elevated circulating creatinine concentration. May not explain all symptoms.

+3. Lysosomal storage disorder: Consistent with intellectual disability, cerebral atrophy, kyphoscoliosis, body odor. May not explain all metabolic abnormalities.

+4. Mitochondrial disorder: Consistent with psychosis, intellectual disability, cerebral atrophy, anemia, osteoporosis, kyphoscoliosis, death in adolescence/early adulthood. May not explain all metabolic abnormalities.

+5. Neurodegenerative disorder: Consistent with psychosis, intellectual disability, cerebral atrophy. Does not explain metabolic abnormalities or physical abnormalities.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with the reported symptom of L-2-hydroxyglutaric aciduria. May or may not present with intellectual disability, seizures, ataxia, and tremor.

+2. Leukodystrophy: Consistent with intellectual disability, seizures, ataxia, and tremor. Does not typically involve L-2-hydroxyglutaric aciduria.

+3. Mitochondrial disorder: Consistent with intellectual disability, seizures, ataxia, and tremor. L-2-hydroxyglutaric aciduria is not a common feature.

+4. Neurodegenerative disorder (e.g., ataxia, Huntington's disease): Consistent with intellectual disability, seizures, ataxia, and tremor. Less likely to cause death in childhood. L-2-hydroxyglutaric aciduria is not a typical symptom.

+5. Unspecified genetic or metabolic disorder: Consistent with the combination of intellectual disability, seizures, ataxia, tremor, and potential death in childhood. The presence of L-2-hydroxyglutaric aciduria suggests a metabolic component.",Hereditary metabolic disorders
['Canavan disease'],"+1. Amino acid metabolism disorder: Consistent with abnormal circulating aspartate family amino acid concentration and potentially motor delay and death in infancy if untreated.

+2. Spinal muscular atrophy: Consistent with motor delay and, in severe cases, can be life-threatening in infancy. No mention of abnormal amino acid levels.

+3. Lesch-Nyhan syndrome: Consistent with motor delay and potentially death in infancy. No mention of abnormal amino acid levels.

+4. Congenital brain malformation: Consistent with motor delay and potentially death in infancy if severe. No mention of abnormal amino acid levels.

+5. Muscular dystrophy: Consistent with motor delay and, in severe forms, can be life-threatening in infancy. No mention of abnormal amino acid levels.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Citrullinemia: Consistent with hyperammonemia, elevated plasma citrulline, and neonatal presentation. May not explain increased bilirubin.

+2. Argininosuccinic aciduria: Another urea cycle disorder that fits the hyperammonemia, elevated citrulline, and neonatal onset. May not account for increased bilirubin.

+3. Biliary atresia: A condition affecting bile flow, which could explain the increased bilirubin and potential liver dysfunction. May not fully explain the hyperammonemia or elevated citrulline.

+4. Organic acidemia: A group of metabolic disorders that can present with hyperammonemia and neonatal onset. Specific organic acid levels would need to be evaluated.

+5. Fatty acid oxidation defect: Another metabolic condition that can cause hyperammonemia and neonatal presentation. Additional testing may be needed to confirm this diagnosis.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, dicarboxylic aciduria, 3-methylglutaric aciduria, vomiting, lethargy, and potential early death. May not explain hyperammonemia or recurrent infections.

+2. Urea cycle disorder: Consistent with hyperammonemia, lethargy, recurrent infections, and potential early death. May not explain aciduria or hypoglycemia.

+3. Fatty acid oxidation disorder: Consistent with hypoglycemia, lethargy, metabolic acidosis, and potential early death. May not explain aciduria or hyperammonemia.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, lethargy, neurological symptoms (drowsiness, sleep abnormality), and potential multi-organ involvement. May not explain aciduria or hyperammonemia.

+5. Glycogen storage disease: Consistent with hypoglycemia, hepatomegaly, and potential metabolic abnormalities. May not explain aciduria, hyperammonemia, or neurological symptoms.",Hereditary metabolic disorders
['Cystinuria'],"+1. Lysosomal storage disorder: Consistent with seizures, splenomegaly, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific organ involvement (e.g., liver, bone, brain).

+2. Mitochondrial disorder: Consistent with seizures, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific neurological or muscular manifestations.

+3. Leukodystrophy: Consistent with seizures, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific neurological deficits or regression.

+4. Severe combined immunodeficiency (SCID): Consistent with respiratory insufficiency and potential death in infancy. Key symptoms not reported: recurrent infections, failure to thrive.

+5. Congenital muscular dystrophy: Consistent with respiratory insufficiency and potential death in infancy. Key symptoms not reported: specific muscle weakness or deformities.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Urea cycle disorder: Consistent with intellectual disability, hyperammonemia, hypoproteinemia, increased blood urea nitrogen, and neonatal/infant death. May not fully explain motor delay, hypotonia, or amino acid abnormalities.

+2. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with intellectual disability, motor delay, hypotonia, hyperammonemia, methylmalonic aciduria, and amino acid abnormalities. May not fully explain hypoproteinemia or increased blood urea nitrogen.

+3. Maple syrup urine disease (MSUD): Consistent with intellectual disability, motor delay, hypotonia, hypervalinemia, abnormal isoleucine levels, and feeding difficulties. May not explain hyperammonemia, hypoproteinemia, or methylmalonic aciduria.

+4. Mitochondrial disorder: Consistent with intellectual disability, motor delay, hypotonia, feeding difficulties, and multi-system involvement. Additional symptoms or test results would be needed for a more specific diagnosis.

+5. Combined immunodeficiency with metabolic disorder: Consistent with intellectual disability, motor delay, hypotonia, recurrent viral infections, and metabolic abnormalities. Additional immunological workup and specific metabolic testing would be required for a definitive diagnosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and elevated urinary carboxylic acid. May not fully explain the recurrent infections or early mortality.

+2. Tyrosinemia: Consistent with hypertyrosinemia and elevated urinary carboxylic acid. May not fully explain the recurrent infections or early mortality.

+3. Severe Combined Immunodeficiency (SCID): Consistent with recurrent viral infections and early mortality. May not explain the metabolic abnormalities.

+4. Leukocyte Adhesion Deficiency (LAD): Consistent with recurrent infections and early mortality. May not explain the metabolic abnormalities.

+5. Chromosomal abnormality or genetic syndrome: Could potentially explain the combination of metabolic and immunological issues, as well as early mortality. Additional testing may be needed to identify the specific condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, intellectual disability, and potential developmental abnormalities. Key symptom not reported: seizures.

+2. Tyrosinemia: Consistent with hypertyrosinemia, intellectual disability, and potential developmental abnormalities. Key symptoms not reported: liver dysfunction, rickets.

+3. Down syndrome: Consistent with intellectual disability, potential prenatal/birth abnormalities, and potential early mortality. Key symptoms not reported: characteristic facial features, congenital heart defects.

+4. Prader-Willi syndrome: Consistent with intellectual disability, obesity, and potential early mortality. Key symptoms not reported: hypotonia, hypogonadism, behavioral issues.

+5. Congenital malformation syndrome: Consistent with multiple congenital abnormalities, intellectual disability, and potential early mortality. Additional information needed to specify the syndrome.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. May also cause oroticaciduria.

+2. Citrullinemia: Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. May also cause oroticaciduria.

+3. Hemophilia: Consistent with abnormal bleeding and abnormality of the coagulation cascade. Does not typically cause the other reported symptoms.

+4. Liver disease or failure: Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. Death in infancy is not a common presentation.

+5. Metabolic disorder affecting pyrimidine metabolism: Consistent with oroticaciduria and potentially vomiting. May not explain the other reported symptoms.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with intellectual disability, generalized hypotonia, hyperammonemia, abnormal cerebral morphology, abnormal myelination, and L-2-hydroxyglutaric acidemia. No key symptoms missing.

+2. Leukodystrophy: Consistent with intellectual disability, abnormal cerebral morphology, and abnormal myelination. Does not typically present with hyperammonemia or L-2-hydroxyglutaric acidemia.

+3. Urea cycle disorder: Consistent with intellectual disability, hyperammonemia, and abnormal cerebral morphology. Does not typically present with abnormal myelination or L-2-hydroxyglutaric acidemia.

+4. Mitochondrial disorder: Consistent with intellectual disability, generalized hypotonia, and abnormal cerebral morphology. May present with hyperammonemia, but does not typically involve L-2-hydroxyglutaric acidemia or abnormal myelination.

+5. Peroxisomal disorder: Consistent with intellectual disability, generalized hypotonia, and abnormal cerebral morphology. May present with abnormal myelination, but does not typically involve hyperammonemia or L-2-hydroxyglutaric acidemia.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia: Intellectual disability, ataxia, cerebellar atrophy, and increased risk of thromboembolism are consistent with this genetic disorder. However, the patient did not report the characteristic telangiectasias (dilated blood vessels).

+2. Joubert syndrome: Intellectual disability, ataxia, and cerebellar agenesis or hypoplasia (underdevelopment) are hallmarks of this congenital brain malformation. Stroke-like episodes and thromboembolism are not typical features.

+3. Dandy-Walker malformation: This congenital brain malformation can cause intellectual disability, ataxia, and cerebellar abnormalities. However, it does not typically involve thromboembolism or stroke-like episodes.

+4. Congenital disorder of glycosylation: A group of inherited metabolic disorders that can lead to intellectual disability, ataxia, cerebellar atrophy, and stroke-like episodes. Thromboembolism is not a common feature.

+5. Mitochondrial encephalomyopathy: A group of disorders caused by mitochondrial dysfunction, which can manifest with intellectual disability, ataxia, cerebellar atrophy, and stroke-like episodes. Thromboembolism is not a typical symptom.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, premature birth, and neonatal death. Key symptom not reported: liver and kidney failure.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, premature birth, and neonatal death. Key symptoms not reported: intellectual disability, seizures, and neurological problems.

+3. Maple syrup urine disease (MSUD): Consistent with premature birth and neonatal death. Key symptoms not reported: maple syrup odor in urine, lethargy, and neurological problems.

+4. Congenital metabolic disorder (unspecified): Consistent with premature birth, neonatal death, hypertyrosinemia, and hyperphenylalaninemia. Additional information is needed to narrow down the specific disorder.

+5. Severe genetic disorder (unspecified): Consistent with premature birth, neonatal death, and potentially life-threatening condition. Additional information is needed to identify the specific disorder.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism: Delayed speech and language development, intellectual disability, seizures, lethargy, motor delay, generalized hypotonia, tremor, hyperammonemia, increased circulating lactate concentration, hyperglycinemia, hypertyrosinemia, hyperalaninemia, hyperprolinemia, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia.

+2. Neurodegenerative disorder: Delayed speech and language development, intellectual disability, seizures, lethargy, motor delay, generalized hypotonia, tremor, difficulty walking, difficulty climbing stairs, difficulty running, sleep abnormality.

+3. Primary immunodeficiency: Leukopenia, recurrent viral infections, fever, pneumonia.

+4. Congenital disorder of glycosylation: Delayed speech and language development, intellectual disability, seizures, lethargy, motor delay, generalized hypotonia, tremor, increased circulating lactate concentration, stomatitis.

+5. Chromosomal abnormality or genetic syndrome: Delayed speech and language development, intellectual disability, seizures, lethargy, motor delay, generalized hypotonia, tremor, neonatal death, death in infancy, death in childhood.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Decreased circulating ceruloplasmin concentration, decreased circulating copper concentration, elevated circulating hepatic transaminase concentration. Key symptom not reported: neurological symptoms (e.g., tremors, speech difficulties).

+2. Liver disease (e.g., hepatitis, cirrhosis): Elevated circulating hepatic transaminase concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration. Key symptom not reported: jaundice, abdominal pain, fatigue.

+3. Diabetes mellitus: Polydipsia. Key symptoms not reported: polyuria (frequent urination), polyphagia (increased hunger), weight loss.

+4. Inherited metabolic disorder (other than Wilson's disease): Decreased circulating ceruloplasmin concentration, decreased circulating copper concentration, elevated circulating hepatic transaminase concentration. Key symptoms may vary depending on the specific disorder.

+5. Dehydration: Polydipsia. Key symptoms not reported: decreased urine output, dry mouth, dizziness, fatigue.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperglutaminemia, oroticaciduria, neurological symptoms (seizures, lethargy, hypotonia), and potential for early death. Key symptoms like hyperammonemia may not have been reported.

+2. Organic acidemia: Matches oroticaciduria, neurological symptoms, and potential for early death. Specific metabolic abnormalities (e.g., elevated organic acids) may not have been reported.

+3. Mitochondrial disorder: Consistent with multi-system involvement, neurological symptoms, and potential for early death. Specific findings like lactic acidosis or muscle weakness may not have been reported.

+4. Leukodystrophy: Matches neurological symptoms (seizures, hypotonia) and potential for progressive deterioration. Specific findings like white matter abnormalities on neuroimaging may not have been reported.

+5. Neurodegenerative disorder: Consistent with neurological symptoms (seizures, hypotonia) and potential for early death. Specific findings like developmental regression or characteristic brain imaging findings may not have been reported.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Inborn error of metabolism: Consistent with abnormality of galactoside metabolism, hypergalactosemia, anemia, elevated alkaline phosphatase, and potential lethality. May not fully explain microcephaly and intellectual disability.

+2. Chromosomal abnormality or genetic syndrome: Consistent with microcephaly, intellectual disability, developmental delays, and abnormality of prenatal development or birth. May not account for metabolic findings.

+3. Congenital infection (e.g., TORCH infections): Consistent with microcephaly, intellectual disability, and developmental delays. Less likely to cause metabolic abnormalities.

+4. Neurodegenerative disorder (e.g., leukodystrophy, neuronal ceroid lipofuscinosis): Consistent with developmental delays, intellectual disability, and potential lethality. Less likely to cause metabolic findings.

+5. Genetic disorder affecting brain development and metabolism: Consistent with the combination of neurological and metabolic symptoms. Specific diagnosis would require further testing and evaluation.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, potential for early death if untreated. May or may not present with obesity or abnormal foot morphology.

+2. Organic acidemia: Consistent with hyperammonemia, potential for early death if untreated. May or may not present with obesity or abnormal foot morphology.

+3. Prader-Willi syndrome: Consistent with obesity, abnormal foot morphology. May or may not present with hyperammonemia or early death.

+4. Cirrhosis or liver disease: Consistent with hyperammonemia. Typically does not present with obesity, abnormal foot morphology, or early death in childhood.

+5. Genetic syndrome with dysmorphic features: Consistent with obesity, abnormal foot morphology, potential for early death. May or may not present with hyperammonemia.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Abnormal myelination, hyperactivity, potential death in infancy. Key symptoms not reported: Vision problems, muscle weakness.

+2. Organic acidemia: Abnormal circulating aspartate family amino acid concentration, potential death in infancy, feeding difficulties. Key symptoms not reported: Vomiting, lethargy, metabolic acidosis.

+3. Mitochondrial disorder: Abnormal myelination, hyperactivity, feeding difficulties, potential death in infancy. Key symptoms not reported: Muscle weakness, seizures, vision/hearing problems.

+4. Peroxisomal disorder: Abnormal myelination, feeding difficulties, potential death in infancy. Key symptoms not reported: Liver dysfunction, skeletal abnormalities, hearing/vision problems.

+5. Neurodegenerative disorder: Hyperactivity, abnormal myelination, feeding difficulties, potential death in infancy. Key symptoms not reported: Seizures, vision problems, cognitive decline.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May not fully explain abnormal prenatal development or infant death unless severe and untreated.

+2. Congenital malformations or birth defects: Consistent with abnormality of prenatal development or birth. Specific condition unknown without further details.

+3. Inborn errors of metabolism (e.g., maple syrup urine disease, homocystinuria): Consistent with hyperphenylalaninemia, abnormal prenatal development, and infant death.

+4. Chromosomal abnormalities: Consistent with abnormality of prenatal development or birth and potentially infant death. Hyperphenylalaninemia not typically associated.

+5. Severe perinatal infections: Consistent with abnormal prenatal development and infant death. Hyperphenylalaninemia not commonly associated.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and delayed speech/language development. May not fully explain prenatal/birth abnormalities or early mortality.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential liver dysfunction leading to early mortality. May not explain all developmental delays.

+3. Chromosomal abnormality or genetic syndrome: Could account for prenatal/birth abnormalities, developmental delays, and early mortality. Specific syndrome would depend on genetic testing results.

+4. Severe neurological disorder or brain malformation: Consistent with developmental delays and potential early mortality. May not explain metabolic abnormalities.

+5. Mitochondrial disorder: Could lead to multisystem involvement, including developmental delays, metabolic abnormalities, and potential early mortality. Specific disorder would depend on genetic testing results.",Hereditary metabolic disorders
[],"+1. Congenital heart disease: Consistent with ventricular septal defect, cardiomyopathy, and pulmonic stenosis. May not fully explain other symptoms like nephritis and hypotonia.

+2. Genetic syndrome: Could account for the multi-system involvement (heart, kidneys, muscles) and early mortality. Specific syndrome would need to be identified through genetic testing.

+3. Metabolic disorder: Certain metabolic disorders can affect multiple organ systems and present with cardiomyopathy, nephritis, and hypotonia. Further metabolic testing would be needed.

+4. Congenital anomalies syndrome: A syndrome involving multiple congenital anomalies could explain the diverse symptoms across different organ systems.

+5. Neonatal sepsis: Severe infection in a newborn can sometimes lead to multi-organ dysfunction, including kidney and heart involvement. However, the reported symptoms may not fully align with this diagnosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Consistent with hypertyrosinemia, neurological symptoms (irritability, spasticity, hyperreflexia), and potential life-threatening complications (death in infancy, childhood, or adolescence). Key symptoms not reported: liver disease, kidney disease, and developmental delays.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and neurological symptoms (irritability, spasticity, hyperreflexia). Key symptoms not reported: musty odor, eczematous rash, fair skin and hair, and intellectual disability if untreated.

+3. Lesch-Nyhan syndrome: Consistent with neurological symptoms (irritability, spasticity, hyperreflexia), recurrent viral infections, and metabolic abnormalities (hyperphenylalaninemia). Key symptom not reported: self-mutilating behavior.

+4. Cerebral palsy: Consistent with neurological symptoms (irritability, spasticity, hyperreflexia). Key symptoms not reported: abnormal muscle tone, movement disorders, and developmental delays.

+5. Primary immunodeficiency disorder: Consistent with recurrent viral infections. Key symptoms not reported: specific immunological abnormalities, and the reported neurological and metabolic symptoms are not typical.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potential developmental abnormalities and early death. Additional metabolic testing needed to identify the specific disorder.

+2. Congenital malformation: Abnormality of prenatal development or birth, potentially leading to neonatal death. Imaging studies and detailed description of the malformations would aid diagnosis.

+3. Chromosomal abnormality or genetic disorder: Abnormal prenatal development, potential metabolic abnormalities, and early death. Genetic testing (e.g., chromosomal analysis, gene panels) could identify the underlying condition.

+4. Perinatal complications: Abnormality of prenatal development or birth, potentially leading to neonatal death. Detailed prenatal and birth history would provide more insights.

+5. Congenital infection: Abnormality of prenatal development, though no specific symptoms suggestive of an infection were provided. Testing for TORCH infections or other congenital infections may be warranted.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, developmental delays, and potential for severe complications if untreated. Key symptom not reported: seizures.

+2. Tyrosinemia: Consistent with hypertyrosinemia, developmental delays, and potential for liver disease and early death if untreated. Key symptoms not reported: liver dysfunction, rickets, and neurological crises.

+3. Chromosomal abnormality (e.g., Down syndrome, Trisomy 18): Consistent with abnormality of prenatal development, developmental delays, and hypotonia. Key symptoms not reported: characteristic facial features and other congenital malformations.

+4. Congenital brain malformation (e.g., lissencephaly, holoprosencephaly): Consistent with abnormality of prenatal development, developmental delays, hypotonia, and potential for early death. Key symptom not reported: seizures.

+5. Neurodegenerative disorder (e.g., Leigh syndrome, Infantile Neuroaxonal Dystrophy): Consistent with developmental regression, hypotonia, and potential for early death. Key symptoms not reported: specific neurological signs and symptoms based on the disorder.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, encephalopathy, seizures, opisthotonus, and potential early death. Key symptom not reported: macrocephaly (enlarged head).

+2. Leigh syndrome: Consistent with encephalopathy, seizures, and opisthotonus. Key symptoms not reported: respiratory difficulties, muscle weakness, and specific neuroimaging findings.

+3. Pyridoxine-dependent epilepsy: Consistent with seizures, encephalopathy, and potential early death. Key symptoms not reported: specific seizure semiology and response to pyridoxine.

+4. Mitochondrial disorders: Consistent with encephalopathy, seizures, and metabolic abnormalities. Key symptoms not reported: specific neurological or systemic manifestations depending on the disorder.

+5. Organic acidemias (other than GA1): Consistent with metabolic abnormalities, including elevated urinary carboxylic acids. Key symptoms not reported: specific metabolic derangements and clinical presentations depending on the disorder.",Hereditary metabolic disorders
[],"+1. Mitochondrial disease: Consistent with neurological symptoms (seizures, hypotonia, spasticity), metabolic acidosis, respiratory issues (cyanosis, dyspnea), and multi-system involvement. Key symptoms not reported: Lactic acidosis, muscle weakness, exercise intolerance.

+2. Leukodystrophy: Fits the neurological symptoms (intellectual disability, seizures, spasticity), but may not fully explain the metabolic and respiratory issues. Key symptoms not reported: Progressive neurological deterioration, specific MRI findings.

+3. Inborn error of metabolism: Consistent with metabolic acidosis, hyperkalemia, hypocalcemia, and some neurological symptoms. Key symptoms not reported: Specific metabolic abnormalities based on the type of disorder.

+4. Neuromuscular disorder: Matches the neurological symptoms (hypotonia, spasticity, motor delay) and respiratory issues (dyspnea, stridor). Key symptoms not reported: Muscle weakness, specific patterns of muscle involvement.

+5. Genetic syndrome: Some syndromes can present with a combination of neurological, metabolic, and respiratory symptoms, but more specific features would be needed for a definitive diagnosis. Key symptoms not reported: Dysmorphic features, specific patterns of involvement.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia (A-T): Consistent with strabismus, intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, reduced antithrombin III activity, and increased risk of death. Key symptom not reported: telangiectasias.

+2. Niemann-Pick disease type C: Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and lipodystrophy. Key symptoms not reported: enlarged spleen, lung involvement.

+3. Zellweger spectrum disorders (peroxisomal biogenesis disorders): Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and potential early death. Key symptoms not reported: hearing loss, vision problems.

+4. Leigh syndrome (mitochondrial disorder): Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and potential early death. Key symptoms not reported: seizures, stroke-like episodes.

+5. MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes): Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and potential early death. Key symptoms not reported: stroke-like episodes, seizures.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease: Consistent with seizures, hypotonia, hyperreflexia, feeding difficulties, and abnormal circulating aspartate family amino acid concentration. Classic symptom of maple syrup odor in urine may not be present.

+2. Phenylketonuria: Consistent with seizures, hypotonia, hyperreflexia, feeding difficulties, and abnormal circulating aspartate family amino acid concentration. Lack of reported developmental delay or intellectual disability.

+3. Infantile spasms: Consistent with seizures, hypotonia, and feeding difficulties. Lack of reported hypsarrhythmia pattern on EEG.

+4. Hypoxic-ischemic encephalopathy: Consistent with seizures, hypotonia, hyperreflexia, and feeding difficulties. Lack of reported perinatal complications or risk factors.

+5. Meningitis: Consistent with seizures, irritability, and feeding difficulties. Lack of reported fever, headache, or other signs of infection.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, gastrointestinal inflammation. Key missing symptom: specific metabolic disorder not specified.

+2. Chromosomal abnormality or genetic syndrome: Abnormality of prenatal development or birth, death in infancy, hypertyrosinemia, hyperphenylalaninemia, gastrointestinal inflammation. Key missing symptom: specific syndrome or chromosomal disorder not identified.

+3. Congenital malformation or birth defect: Abnormality of prenatal development or birth, death in infancy, gastrointestinal inflammation. Key missing symptom: specific malformation or affected organ system not specified.

+4. Glycogen storage disease: Hypertyrosinemia, hyperphenylalaninemia, gastrointestinal inflammation. Key missing symptom: specific glycogen storage disorder not identified.

+5. Mitochondrial disorder: Abnormality of prenatal development or birth, death in infancy, hypertyrosinemia, hyperphenylalaninemia, gastrointestinal inflammation. Key missing symptom: specific mitochondrial disorder not specified.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Leukodystrophy: Consistent with ataxia, coma, reduced tendon reflexes, cerebral edema, abnormal cerebral white matter morphology, and potential death in childhood or adolescence. Key symptom not reported: progressive cognitive and motor decline.

+2. Maple syrup urine disease: Consistent with ataxia, coma, reduced tendon reflexes, metabolic acidosis, hyperleucinemia, and potential death in childhood or adolescence. Key symptom not reported: maple syrup odor in urine and sweat.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potential death in childhood or adolescence. Key symptoms not reported: failure to thrive, chronic diarrhea, and opportunistic infections.

+4. Mitochondrial encephalomyopathy: Consistent with ataxia, coma, reduced tendon reflexes, cerebral edema, and potential death in childhood or adolescence. Key symptoms not reported: seizures, muscle weakness, and vision or hearing problems.

+5. Adrenoleukodystrophy: Consistent with ataxia, coma, reduced tendon reflexes, cerebral edema, abnormal cerebral white matter morphology, and potential death in childhood or adolescence. Key symptom not reported: progressive vision loss or blindness.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Acute intermittent porphyria (AIP): Consistent with abdominal pain and elevated urinary ALA. Typically does not cause death in childhood unless severe and untreated.

+2. Hereditary tyrosinemia type 1: Consistent with abdominal pain, elevated urinary ALA, and potential for death in childhood if untreated.

+3. Acute hepatic porphyria: Consistent with abdominal pain and elevated urinary ALA. Death in childhood is less common unless the condition is severe and untreated.

+4. Lead poisoning: Consistent with abdominal pain and elevated urinary ALA. Death in childhood is less likely unless exposure is extremely high.

+5. Abdominal malignancy: Consistent with abdominal pain. Elevated urinary ALA and death in childhood are less typical findings.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with symptoms of methylmalonic aciduria, metabolic acidosis, seizures, and potential for neonatal death or death in infancy.

+2. Propionic acidemia: Consistent with symptoms of methylmalonic aciduria, metabolic acidosis, seizures, and potential for neonatal death or death in infancy.

+3. Organic acidemias: Consistent with symptoms of methylmalonic aciduria, metabolic acidosis, seizures, and potential for neonatal death or death in infancy.

+4. Mitochondrial disorders: Consistent with symptoms of metabolic acidosis, seizures, and potential for neonatal death or death in infancy. However, methylmalonic aciduria is not a typical feature.

+5. Neonatal epilepsy syndromes: Consistent with symptoms of seizures and potential for neonatal death or death in infancy. However, metabolic acidosis and methylmalonic aciduria are not typical features.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Metabolic disorder: Consistent with seizures, lethargy, growth delay, dark urine. May not explain hypotonia or sleep abnormality.

+2. Leukodystrophy or neurodegenerative disorder: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, sleep abnormality. May not explain dark urine.

+3. Mitochondrial disorder: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, sleep abnormality, dark urine. Often associated with death in childhood.

+4. Neuromuscular disorder: Consistent with hypotonia, lethargy, drowsiness. May not explain seizures, growth delay, or dark urine.

+5. Epilepsy syndrome or brain malformation: Consistent with seizures, lethargy, drowsiness, sleep abnormality, growth delay. May not explain hypotonia or dark urine.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with abnormal circulating levels of leucine, isoleucine, and valine, as well as seizures and potential for early death. Key symptom not reported: Distinctive maple syrup odor in urine and body fluids.

+2. Phenylketonuria (PKU): Consistent with aminoaciduria and potential for seizures and developmental delays. Key symptom not reported: Elevated levels of phenylalanine in blood and urine.

+3. Homocystinuria: Consistent with aminoaciduria and potential for seizures and developmental delays. Key symptom not reported: Elevated levels of homocysteine in blood and urine.

+4. Urea cycle disorder: Consistent with aminoaciduria and potential for seizures and early death. Key symptom not reported: Elevated levels of ammonia in blood.

+5. Mitochondrial disorder: Consistent with seizures and potential for early death. Key symptoms not reported: Muscle weakness, vision or hearing problems, developmental delays.",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with hypoglycemia, cardiomegaly, hepatomegaly, dicarboxylic aciduria, and abnormal carnitine levels. May not fully explain neonatal/childhood deaths or recurrent infections.

+2. Mitochondrial disorder: Consistent with multi-organ involvement (cardiomegaly, hepatomegaly), lactic acidosis, and potential energy deficiency. May not directly explain dicarboxylic aciduria or abnormal carnitine levels.

+3. Primary carnitine deficiency: Consistent with abnormal carnitine levels, hypoglycemia, and potential energy deficiency. May not fully explain cardiomegaly, hepatomegaly, or dicarboxylic aciduria.

+4. Organic acidemia: Consistent with dicarboxylic aciduria, hypoglycemia, and potential energy deficiency. May not directly explain cardiomegaly or hepatomegaly.

+5. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Does not directly explain metabolic or multi-organ involvement.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Glutaric acidemia type I (GA1): Consistent with seizures, lethargy, metabolic acidosis, hypoglycemia, progressive neurologic deterioration, glutaric aciduria. Key symptoms not reported: macrocephaly, dystonia.

+2. Methylglutaconic aciduria: Consistent with 3-methylglutaric aciduria, lethargy, metabolic acidosis, progressive neurologic deterioration. Key symptoms not reported: ataxia, optic atrophy.

+3. Mitochondrial disorder: Consistent with seizures, lethargy, metabolic acidosis, hypoglycemia, progressive neurologic deterioration, fever, vomiting, sleep abnormality. Key symptoms not specified.

+4. Inborn error of amino acid metabolism: Consistent with seizures, lethargy, metabolic acidosis, hypoglycemia, progressive neurologic deterioration, abnormal circulating glycine concentration, elevated urinary carboxylic acid. Specific disorder not identified.

+5. Inborn error of energy metabolism: Consistent with seizures, lethargy, metabolic acidosis, hypoglycemia, progressive neurologic deterioration, fever, vomiting, drowsiness. Specific disorder not identified.",Hereditary metabolic disorders
['MODY'],"+1. Diabetes mellitus: Consistent with hypoglycemia and glycosuria. May not explain abnormal porphyrin levels.

+2. Porphyria: Consistent with abnormal porphyrin levels. Hypoglycemia and glycosuria are less common symptoms.

+3. Liver disease: Consistent with all three symptoms (hypoglycemia, glycosuria, and abnormal porphyrin levels).

+4. Kidney disease: Consistent with glycosuria. May not fully explain hypoglycemia and abnormal porphyrin levels.

+5. Endocrine disorder: Consistent with hypoglycemia and potentially abnormal porphyrin levels. Glycosuria may or may not be present, depending on the specific condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Classic symptoms include intellectual disability, seizures, and behavioral problems if left untreated.

+2. Trisomy disorders (e.g., Down syndrome): Consistent with abnormality of prenatal development and potential for neonatal death. Common features include intellectual disability, congenital malformations, and developmental delays.

+3. Neural tube defects (e.g., spina bifida): Consistent with abnormality of prenatal development and potential for neonatal death. Characterized by malformations of the brain, spine, or spinal cord.

+4. Organic acidemias: Consistent with hyperphenylalaninemia and potential for abnormal development and neonatal death. Caused by defects in amino acid metabolism, leading to buildup of toxic compounds.

+5. Congenital infections (e.g., cytomegalovirus, rubella): Consistent with abnormality of prenatal development and potential for neonatal death. Can cause a range of birth defects and developmental problems depending on the timing and severity of infection.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Leukodystrophy: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, dystonia, hyperreflexia, cerebral atrophy, and early death. May not explain systemic symptoms like fever, vomiting, and anemia.

+2. Lysosomal storage disorder: Matches neurological symptoms, hydrocephalus, macrocephaly, and systemic involvement (anemia, recurrent infections). May not account for increased CSF protein concentration.

+3. Glutaric aciduria type 1: Consistent with macrocephaly, dystonia, seizures, and aciduria (increased CSF protein concentration). May not explain cerebral atrophy or early death.

+4. Neurodegenerative disorder: Fits the progressive neurological decline, cerebral atrophy, and early death. May not explain hydrocephalus or systemic symptoms.

+5. Congenital infection: Could cause hydrocephalus, seizures, and developmental delays. May not account for the full symptom spectrum, especially metabolic abnormalities.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May also present with developmental delays, seizures, and other neurological symptoms if untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia. Can lead to liver disease, kidney dysfunction, and neurological complications if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential for early mortality. Examples include trisomies, neural tube defects, and multiple congenital anomaly syndromes.

+4. Severe perinatal asphyxia: Consistent with neonatal death or developmental abnormalities due to lack of oxygen during the perinatal period.

+5. Prematurity complications: Consistent with neonatal death or developmental abnormalities in premature infants due to immature organ systems and potential complications.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Patients may also experience developmental delays, seizures, and other neurological symptoms if left untreated.

+2. Tyrosinemia type I: Consistent with hypertyrosinemia. Patients may also experience liver disease, kidney problems, and neurological symptoms if left untreated.

+3. HELLP syndrome (a severe form of preeclampsia): Consistent with preeclampsia. Patients may also experience hemolysis, elevated liver enzymes, and low platelet count.

+4. Acute fatty liver of pregnancy (AFLP): Consistent with preeclampsia. Patients may also experience nausea, vomiting, abdominal pain, and liver failure.

+5. Mitochondrial disorder: Consistent with death in early adulthood and potential metabolic abnormalities. Patients may also experience muscle weakness, neurological symptoms, and multi-organ dysfunction.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, potentially leading to developmental abnormalities and intellectual disability if untreated. Key symptom not reported: fair skin and hair.

+2. Tyrosinemia type I: Hypertyrosinemia, elevated urinary carboxylic acid, potentially leading to liver failure, neurological problems, and early death if untreated.

+3. Maple syrup urine disease (MSUD): Elevated branched-chain amino acids (leucine, isoleucine, valine), potentially leading to metabolic decompensation, neurological symptoms, and early mortality if untreated.

+4. Zellweger syndrome: A peroxisomal disorder causing developmental abnormalities, liver dysfunction, and early mortality. Key symptoms not reported: hypotonia, seizures, and distinctive facial features.

+5. Trisomy 18 (Edwards syndrome): A chromosomal disorder causing multiple congenital malformations, developmental delays, and high mortality in infancy. Key symptoms not reported: characteristic facial features and structural abnormalities.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential for developmental abnormalities, intellectual disability, and early death if untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential for liver disease, neurological problems, and early death if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential for multi-organ involvement leading to early mortality. Common symptoms not reported (e.g., dysmorphic features, organ malformations).

+4. Severe perinatal asphyxia: Consistent with potential for neonatal death or developmental abnormalities due to lack of oxygen during birth. Specific symptoms not provided.

+5. Prematurity complications: Consistent with potential for neonatal death or developmental abnormalities due to premature birth. Specific symptoms not provided.",Hereditary metabolic disorders
['Hereditary orotic aciduria'],"+1. Inborn error of metabolism: Consistent with metabolic abnormalities, multi-system involvement, and early onset. Key symptoms not reported: specific metabolic derangements or dysmorphic features associated with certain disorders.

+2. Immunodeficiency: Consistent with recurrent infections, skin rash, and hepatosplenomegaly. Key symptoms not reported: specific laboratory abnormalities or clinical features of particular immunodeficiencies.

+3. Sepsis: Consistent with fever, lethargy, and multi-organ involvement. Key symptoms not reported: specific source of infection or positive blood cultures.

+4. Malignancy: Consistent with hepatosplenomegaly, lethargy, and metabolic abnormalities. Key symptoms not reported: specific tumor markers or imaging findings.

+5. Autoimmune or inflammatory disorder: Consistent with multi-system involvement and skin manifestations. Key symptoms not reported: specific autoantibodies or clinical features of particular disorders.",Hereditary metabolic disorders
['Holocarboxylase synthetase deficiency'],"+1. Organic acidemia: Consistent with metabolic acidosis, hyperammonemia, aminoaciduria, abnormal circulating monocarboxylic acid and carboxylic acid levels. Key symptoms like vomiting and lethargy are not mentioned.

+2. Respiratory distress syndrome: Consistent with cyanosis, tachypnea, and hypotonia. Does not explain metabolic abnormalities.

+3. Congenital heart defect: Consistent with cyanosis and tachypnea. Does not explain metabolic abnormalities.

+4. Sepsis: Consistent with tachypnea and metabolic acidosis. Fever and poor feeding, which are common in sepsis, are not mentioned.

+5. Inborn error of glycine metabolism: Consistent with abnormal circulating glycine concentration. Does not explain other metabolic abnormalities.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, lethargy, vomiting, and potential for early death. Key symptoms like protein aversion and episodic nature not reported.

+2. Leukodystrophy: Consistent with ataxia, lethargy, drowsiness, sleep abnormality, and potential for early death. Metabolic abnormalities like hyperammonemia and oroticaciduria not typical.

+3. Mitochondrial disorder: Consistent with ataxia, lethargy, vomiting, drowsiness, and potential for early death. Specific metabolic abnormalities like hyperammonemia and oroticaciduria not characteristic.

+4. Organic acidemia: Consistent with lethargy, vomiting, hyperammonemia, and potential for early death. Oroticaciduria not a common feature.

+5. Unspecified inherited metabolic disorder: Consistent with the combination of neurological symptoms, metabolic abnormalities, and potential for early death. Specific diagnosis unclear based on the provided information.",Hereditary metabolic disorders
[],"+1. Ethylmalonic encephalopathy (EE): Consistent with ethylmalonic aciduria, abnormal carnitine levels, decreased 3-hydroxyacyl-CoA dehydrogenase activity, vomiting, and early childhood/adolescent death.

+2. Glutaric acidemia type II: Consistent with ethylmalonic aciduria, abnormal carnitine levels, and decreased 3-hydroxyacyl-CoA dehydrogenase activity. Key symptoms like hypoglycemia, metabolic acidosis, and neurological issues are not reported.

+3. Multiple acyl-CoA dehydrogenase deficiency (MADD): Consistent with ethylmalonic aciduria, abnormal carnitine levels, and decreased 3-hydroxyacyl-CoA dehydrogenase activity. Symptoms like hypoglycemia, vomiting, and lethargy during fasting or illness are not explicitly mentioned.

+4. Carnitine palmitoyltransferase II (CPT II) deficiency: Consistent with abnormal carnitine levels and decreased 3-hydroxyacyl-CoA dehydrogenase activity. Key symptoms like muscle weakness, rhabdomyolysis, and myoglobinuria are not reported.

+5. Organic aciduria: A general term for a group of inherited metabolic disorders characterized by the accumulation of organic acids, including ethylmalonic acid, in the body. Consistent with ethylmalonic aciduria and abnormal carnitine levels.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with dysmorphic facial features, developmental delays, musculoskeletal abnormalities, feeding difficulties, hypocholesterolemia, elevated 8-dehydrocholesterol, and elevated circulating 7-dehydrocholesterol concentration.

+2. Trisomy 18 (Edwards syndrome): Consistent with dysmorphic facial features, developmental delays, musculoskeletal abnormalities, and feeding difficulties. Does not typically involve abnormal cholesterol levels.

+3. Congenital myopathies: Consistent with generalized hypotonia and motor delay. Does not typically involve the other reported symptoms.

+4. Prader-Willi syndrome: Consistent with intellectual disability, hypotonia, and feeding difficulties. Does not typically involve dysmorphic facial features or abnormal cholesterol levels.

+5. Unspecified multiple congenital anomalies: Consistent with the combination of dysmorphic features, developmental delays, musculoskeletal abnormalities, and feeding difficulties. Further testing would be needed to determine a specific diagnosis.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Leigh syndrome: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, and abnormal basal ganglia morphology. Early death is a common feature.

+2. Glutaric aciduria type 1: Consistent with intellectual disability, ataxia, cerebral atrophy, abnormal basal ganglia morphology, and L-2-hydroxyglutaric aciduria.

+3. Leukodystrophies: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, and abnormal basal ganglia morphology.

+4. Neuronal ceroid lipofuscinoses (NCLs): Consistent with intellectual disability, ataxia, cerebral atrophy, and abnormal basal ganglia morphology. Seizures, a common symptom, were not reported.

+5. Mitochondrial encephalomyopathies: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, abnormal basal ganglia morphology, and potential for early death.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, dicarboxylic aciduria, 3-methylglutaconic aciduria, seizures, hypotonia, and potential neonatal/childhood death. Key symptoms not reported: specific organic acid elevations in blood/urine.

+2. Leigh syndrome: Consistent with metabolic acidosis, seizures, hypotonia, and potential neonatal/childhood death. Key symptoms not reported: developmental delays, respiratory issues, and specific neuroimaging findings.

+3. Mitochondrial disorder (e.g., MELAS): Consistent with metabolic acidosis, seizures, hypotonia, and potential neonatal/childhood death. Key symptoms not reported: stroke-like episodes, muscle weakness, and specific biochemical/genetic markers.

+4. Early infantile epileptic encephalopathy (EIEE): Consistent with seizures, hypotonia, and potential neonatal/childhood death. Key symptoms not reported: specific EEG patterns, developmental regression, and genetic markers.

+5. Severe neonatal sepsis: Consistent with irritability, seizures, metabolic acidosis, and potential neonatal death. Key symptoms not reported: fever, respiratory distress, and specific laboratory findings (e.g., elevated inflammatory markers).",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Organic aciduria: Consistent with L-2-hydroxyglutaric aciduria, seizures, and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.

+2. Mitochondrial disorder: Could account for the metabolic abnormalities, neurological symptoms (seizures), and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.

+3. Leukodystrophy: A genetic disorder affecting the white matter of the brain, which could explain the neurological symptoms (seizures), metabolic abnormalities, and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.

+4. Vasculitis: An inflammatory condition that could account for the skin rash, fever, and elevated C-reactive protein. May not fully explain the metabolic abnormalities or seizures.

+5. Neurocutaneous syndrome: A group of genetic disorders affecting the skin, brain, and other organs, which could explain the combination of dermatological, neurological, and metabolic symptoms. Key symptoms like tumors or developmental delays may not be present.",Hereditary metabolic disorders
['X-linked hypophosphatemia'],"+1. Hypophosphatemic rickets: Consistent with hypophosphatemia, abnormal limb bone morphology, nephritis, and elevated alkaline phosphatase. Key symptoms not reported: short stature, muscle weakness.

+2. Osteogenesis imperfecta: Consistent with abnormal limb bone morphology and potential for early death. Key symptoms not reported: bone fractures, blue sclera, hearing loss.

+3. Vitamin D deficiency rickets: Consistent with hypophosphatemia, abnormal limb bone morphology, and potential for nephritis. Key symptoms not reported: muscle weakness, bone pain.

+4. Chronic kidney disease: Consistent with nephritis and potential for abnormal hormone levels. Key symptoms not reported: edema, fatigue, nausea.

+5. Metabolic bone disease: Consistent with abnormal limb bone morphology, hypophosphatemia, and elevated alkaline phosphatase. Key symptoms not reported: bone pain, muscle cramps.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism (e.g., organic acidemia or urea cycle disorder): Consistent with hyperammonemia, hyperglycinemia, hyperglycinuria, abnormal amino acid levels, and elevated urinary carboxylic acid. May not fully explain skin rash or leukopenia.

+2. Glycine encephalopathy or serine deficiency disorder: Consistent with hyperglycinemia, hyperglycinuria, abnormal amino acid levels, developmental delay, and elevated alkaline phosphatase. May not explain skin rash or leukopenia.

+3. Combined immunodeficiency disorder: Consistent with leukopenia and skin rash. May not fully explain metabolic abnormalities.

+4. Chromosomal or genetic disorder (e.g., trisomy 21): Consistent with developmental delay and potentially some metabolic abnormalities. May not fully explain the specific metabolic findings or leukopenia.

+5. Malignancy (e.g., leukemia or lymphoma): Consistent with leukopenia and elevated alkaline phosphatase. Does not typically present with the metabolic abnormalities.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, hyperhomocystinemia, developmental delays, hypotonia, and gastrointestinal inflammation. May not cause neonatal/infant death in milder cases.

+2. Propionic acidemia: Consistent with methylmalonic aciduria, hyperhomocystinemia, developmental delays, hypotonia, gastrointestinal inflammation, and abnormal cerebral white matter morphology. Can potentially cause early death in severe cases.

+3. Carnitine deficiency: Consistent with decreased plasma free carnitine, developmental delays, hypotonia, and gastrointestinal inflammation. Does not typically cause aciduria or white matter abnormalities.

+4. Leukodystrophy: Consistent with abnormal cerebral white matter morphology, developmental delays, and hypotonia. Does not typically cause the reported metabolic abnormalities.

+5. Mitochondrial disorder: Consistent with developmental delays, hypotonia, gastrointestinal inflammation, and potentially early death. Does not typically cause the reported metabolic abnormalities.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid and potential for neonatal death if untreated. Key symptoms may include metabolic acidosis, lethargy, vomiting, and developmental delays.

+2. Fatty acid oxidation disorder: Consistent with potential for neonatal death and metabolic decompensation. Key symptoms may include hypoglycemia, liver dysfunction, and cardiomyopathy.

+3. Mitochondrial disorder: Consistent with potential for multi-organ dysfunction and neonatal death. Key symptoms may include neurological abnormalities, muscle weakness, and lactic acidosis.

+4. Congenital anomaly or genetic syndrome: Consistent with potential for neonatal death, but elevated urinary carboxylic acid may not be a typical feature. Additional symptoms may vary depending on the specific condition.

+5. Severe perinatal infection or sepsis: Consistent with potential for neonatal death, although elevated urinary carboxylic acid is not a typical feature. Key symptoms may include fever, respiratory distress, and multi-organ failure.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Hyperammonemia, lethargy, drowsiness, sleep abnormality, feeding difficulties, and potential for neonatal death are consistent with a urea cycle disorder. Key symptoms not reported: vomiting, seizures, and respiratory alkalosis.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Lethargy, spasticity, generalized hypotonia, hyperreflexia, and death in infancy are consistent with a leukodystrophy. Key symptoms not reported: vision loss, seizures, and cognitive decline.

+3. Mitochondrial disorder (e.g., Leigh syndrome, MELAS): Lethargy, spasticity, generalized hypotonia, hyperreflexia, and potential for neonatal death could be seen in mitochondrial disorders. Key symptoms not reported: seizures, stroke-like episodes, and lactic acidosis.

+4. Spinal muscular atrophy (SMA): Generalized hypotonia, feeding difficulties, and potential for neonatal death are consistent with severe forms of SMA. Key symptoms not reported: progressive muscle weakness and respiratory failure.

+5. Congenital myopathy: Generalized hypotonia, feeding difficulties, and potential for neonatal death could be seen in severe congenital myopathies. Key symptoms not reported: specific muscle weakness patterns and respiratory involvement.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in infancy/childhood.

+2. Propionic acidemia: Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in infancy/childhood.

+3. Vitamin B12 deficiency: Consistent with metabolic acidosis and decreased methylmalonyl-CoA mutase activity, but less likely to cause death in infancy/childhood unless severe.

+4. Inborn errors of metabolism (e.g., isovaleric acidemia, glutaric aciduria type II): Consistent with metabolic acidosis and potential for death in infancy/childhood if left untreated.

+5. Renal failure (severe congenital form): Consistent with metabolic acidosis, but less likely to be associated with decreased methylmalonyl-CoA mutase activity or death in infancy/childhood unless a severe congenital form.",Hereditary metabolic disorders
[],"+1. Porphyria: Abnormal circulating porphyrin concentration, potential neurological symptoms (hyperactivity, spasticity), hemolytic anemia, and metabolic acidosis are consistent with acute porphyrias.

+2. Mitochondrial disorder: Metabolic acidosis, neurological symptoms (hyperactivity, spasticity, neonatal death), recurrent viral infections (potential immunodeficiency), and increased lactate dehydrogenase are seen in mitochondrial disorders. Hemolytic anemia is not a typical feature.

+3. Lesch-Nyhan syndrome: Hyperactivity, spasticity, and neonatal/infant death fit this disorder, but hemolytic anemia and metabolic acidosis are not common features.

+4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemolytic anemia is a key symptom, but the neurological symptoms, metabolic acidosis, and abnormal porphyrin levels are not explained by this diagnosis alone.

+5. Congenital immunodeficiency: Recurrent viral infections suggest an immunodeficiency, but the other symptoms (neurological, metabolic, hematological) are not typical of primary immunodeficiencies.",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, elevated plasma citrulline, respiratory distress, and neonatal death. Key symptoms not reported: seizures, lethargy, and vomiting.

+2. Respiratory distress syndrome: Consistent with premature birth, respiratory distress, apnea, and hypoxemia. Does not explain hyperammonemia or elevated citrulline levels.

+3. Congenital heart defect: Consistent with respiratory distress and hypoxemia. Does not explain hyperammonemia, elevated citrulline levels, or neonatal death.

+4. Sepsis: Consistent with respiratory distress, apnea, and respiratory acidosis. Does not explain hyperammonemia or elevated citrulline levels.

+5. Inborn error of metabolism: Consistent with hyperammonemia, elevated plasma citrulline, and neonatal death. Specific disorder not identified based on the given symptoms.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, increased lactate, hyperammonemia, developmental delay, seizures, hypotonia. Key symptom not reported: metabolic acidosis.

+2. Mitochondrial disorder: Consistent with autistic behavior, intellectual disability, seizures, hypotonia, increased lactate, pancreatitis, anemia, acute kidney injury, hyperammonemia, vomiting. Key symptoms not reported: muscle weakness, vision/hearing problems.

+3. Lysosomal storage disorder: Consistent with intellectual disability, seizures, kyphoscoliosis, short femur, organomegaly (if present), multi-organ involvement. Key symptoms not reported: coarse facial features, hepatosplenomegaly, skeletal dysplasia.

+4. Congenital disorder of glycosylation: Consistent with intellectual disability, seizures, hypotonia, multi-organ involvement. Key symptoms not reported: specific dysmorphic features, coagulopathy, protein-losing enteropathy.

+5. Inborn error of metabolism: Consistent with autistic behavior, intellectual disability, seizures, hypotonia, hyperammonemia, hyperglycinemia, methylmalonic acidemia, hyperuricemia, increased lactate, gout, pancreatitis, leukopenia, anemia, acute kidney injury, vomiting. Key symptoms depend on the specific metabolic disorder.",Hereditary metabolic disorders
['Dihydropteridine reductase deficiency'],"+1. Inborn Error of Metabolism: Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, intellectual disability, seizures, and developmental delays. Key symptom not reported: fair skin and hair.

+2. Inborn Error of Metabolism: Tyrosinemia: Consistent with hypertyrosinemia, intellectual disability, seizures, and developmental delays. Key symptoms not reported: liver dysfunction, rickets, and skin abnormalities.

+3. Leukodystrophy: Consistent with abnormal cerebral white matter morphology, motor delays, intellectual disability, and seizures. Key symptoms not reported: specific white matter lesion patterns on brain imaging.

+4. Congenital Brain Malformation: Lissencephaly: Consistent with microcephaly, intellectual disability, seizures, and abnormal brain development. Key symptoms not reported: specific brain imaging findings (e.g., smooth brain surface).

+5. Microcephaly Primordial Dwarfism: Consistent with microcephaly, intellectual disability, seizures, and abnormal prenatal development. Key symptoms not reported: proportionate short stature and specific physical features.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Consistent with cytochrome C oxidase-negative muscle fibers, ethylmalonic aciduria, abnormal glycine concentration, and feeding difficulties. May not explain skin rash.

+2. Metabolic disorder: Consistent with glycosuria, ethylmalonic aciduria, and abnormal glycine concentration. May not explain skin rash or gastrointestinal symptoms.

+3. Immunological disorder: Consistent with skin rash (erythematous plaque, macule, papule). May not explain other symptoms.

+4. Gastrointestinal disorder: Consistent with feeding difficulties and gastrointestinal tract abnormalities. May not explain other symptoms.

+5. Genetic disorder: Consistent with early onset and death in infancy. May explain multiple system involvement but requires further genetic testing.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with cyanosis, seizures, death in infancy, hyperammonemia, cerebral edema, oroticaciduria, and low plasma citrulline. Key symptom not reported: vomiting.

+2. Argininosuccinic aciduria (ASA): Consistent with cyanosis, seizures, death in infancy, hyperammonemia, cerebral edema, hypoargininemia. Key symptom not reported: trichorrhexis nodosa (brittle, kinky hair).

+3. Carbamoyl phosphate synthetase I deficiency (CPS1 deficiency): Consistent with cyanosis, seizures, death in infancy, hyperammonemia, cerebral edema. Key symptom not reported: protein intolerance.

+4. Citrullinemia type I: Consistent with cyanosis, seizures, death in infancy, hyperammonemia, cerebral edema, low plasma citrulline. Key symptom not reported: cholestasis.

+5. Arginase deficiency: Consistent with cyanosis, seizures, death in infancy, hyperammonemia, cerebral edema, hypoargininemia. Key symptom not reported: spastic diplegia.",Hereditary metabolic disorders
['Canavan disease'],"+1. Urea cycle disorders: Consistent with hyperammonemia, seizures, aminoaciduria, abnormal amino acid levels, and potential death in infancy. Key symptom not reported: vomiting, lethargy.

+2. Glycine encephalopathy: Consistent with seizures, abnormal glycine levels, and potential death in infancy. Key symptoms not reported: hypotonia, respiratory distress.

+3. Maple syrup urine disease (MSUD): Consistent with seizures, aminoaciduria, abnormal amino acid levels, and potential death in infancy. Key symptom not reported: maple syrup odor in urine.

+4. Phenylketonuria (PKU): Consistent with seizures and skin rash. Key symptoms not reported: developmental delays, musty odor, and hyperammonemia/aminoaciduria are not typical.

+5. Erythema multiforme: Consistent with the skin rash (erythematous plaques, macules, papules). Key symptoms not reported: mucosal involvement, target lesions, and does not explain the other systemic symptoms.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, seizures, respiratory insufficiency, feeding difficulties. Key symptom not reported: Sweet urine odor.

+2. Nonketotic hyperglycinemia: Consistent with seizures, respiratory insufficiency, neonatal death, feeding difficulties. Key symptoms not reported: Elevated glycine levels, hiccups.

+3. Organic acidemia: Consistent with seizures, respiratory insufficiency, neonatal death, feeding difficulties. Key symptoms not reported: Specific organic acid elevations, metabolic acidosis.

+4. Urea cycle disorder: Consistent with seizures, respiratory insufficiency, neonatal death, feeding difficulties. Key symptoms not reported: Hyperammonemia, elevated urea cycle metabolites.

+5. Neonatal sepsis: Consistent with respiratory insufficiency, feeding difficulties, sepsis. Key symptoms not reported: Fever, elevated inflammatory markers.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorders (FAODs): Consistent with decreased 3-hydroxyacyl-CoA dehydrogenase level, abnormal carnitine concentration, and potential for early mortality.

+2. Congenital malformations: Consistent with abnormality of prenatal development or birth, and potential for early mortality.

+3. Inborn errors of metabolism: Consistent with abnormal metabolic markers (carnitine, enzyme levels), and potential for early mortality.

+4. Genetic syndromes: Consistent with abnormality of prenatal development or birth, obesity, and potential for early mortality.

+5. Perinatal complications: Consistent with abnormality of prenatal development or birth, and potential for early mortality. Additional information on pregnancy, delivery, and neonatal course would be helpful.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Leukodystrophy: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. May not explain hypertyrosinemia or hyperphenylalaninemia.

+2. Phenylketonuria (PKU): Consistent with intellectual disability, seizures, and hyperphenylalaninemia. Does not typically involve white matter abnormalities, dyskinesia, or early death.

+3. Tyrosinemia type I: Consistent with intellectual disability, seizures, hypertyrosinemia, and potential early death. Does not typically involve white matter abnormalities or dyskinesia.

+4. Leigh syndrome: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. Does not typically involve metabolic abnormalities.

+5. Mitochondrial disorder: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. Does not typically involve metabolic abnormalities.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Matches symptoms like low ceruloplasmin, increased urinary copper, hepatomegaly, elevated transaminases, and neurological symptoms (hypotonia). Key symptom not reported: Kayser-Fleischer rings in the cornea.

+2. Lysosomal storage disorder (e.g., Gaucher's disease, Niemann-Pick disease): Consistent with hepatosplenomegaly, hypotonia, and abnormal amino acid levels. Does not typically involve copper-related abnormalities.

+3. Mitochondrial disorder: Could explain hypotonia, liver dysfunction, and amino acid abnormalities. Copper-related findings are not common in these disorders.

+4. Organic acidemia or amino acidopathy: Matches the abnormal amino acid levels. Less consistent with hepatosplenomegaly and copper-related abnormalities.

+5. Neonatal hemochromatosis: A rare disorder causing excessive iron and copper accumulation in the liver, which can lead to liver failure and neurological symptoms. Consistent with hepatomegaly, elevated transaminases, and copper-related findings.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia (A-T): Consistent with ataxia, intellectual disability, cerebellar atrophy, and early mortality. Telangiectasia not reported.

+2. Joubert syndrome: Matches cerebellar agenesis, ataxia, hypotonia, and abnormal facial shape. Intellectual disability not always present.

+3. Leukodystrophy: Consistent with ataxia, intellectual disability, and cerebellar atrophy. Additional details on age and progression would be helpful.

+4. Trisomy 18 (Edwards syndrome): Fits intellectual disability, abnormal calvaria morphology, hypotonia, and early mortality. Ataxia and cerebellar atrophy less common.

+5. Congenital disorder of glycosylation: A group of metabolic disorders that can cause intellectual disability, hypotonia, ataxia, and abnormal facial features. Cerebellar involvement possible but not specified.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia is a key symptom. Untreated PKU can lead to developmental delays, seizures, and intellectual disability.

+2. Tyrosinemia: Hypertyrosinemia is a characteristic finding. Severe forms can cause liver disease, kidney dysfunction, and neurological problems from infancy.

+3. Congenital malformation syndrome: Abnormality of prenatal development or birth, along with potential multi-organ involvement, could indicate a genetic syndrome affecting multiple body systems.

+4. Severe congenital heart defect: Certain complex heart malformations can be life-threatening in infancy or childhood, potentially explaining neonatal or infant death.

+5. Mitochondrial disorder: These inherited conditions can affect multiple organ systems and potentially cause developmental abnormalities, metabolic disturbances, and early mortality.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, hypotonia, abnormal cerebral morphology, increased lactate, and glutaric aciduria. May not explain hypercalcemia or abnormal lysine/carnitine levels.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with macrocephaly, hypotonia, abnormal cerebral morphology, and death in infancy. May not explain metabolic abnormalities.

+3. Mitochondrial disorder: Consistent with hypotonia, increased lactate, and potential neurological symptoms. May not fully explain macrocephaly, hypercalcemia, or specific metabolic abnormalities.

+4. Congenital disorder of glycosylation (CDG): Consistent with hypotonia, developmental delays, and potential metabolic abnormalities. Specific symptoms can vary widely among different CDG types.

+5. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with metabolic abnormalities, hypotonia, and potential neurological symptoms. May not fully explain macrocephaly or hypercalcemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential developmental abnormalities/early death if untreated. Key symptom not reported: intellectual disability.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential developmental abnormalities/early death if untreated. Key symptoms not reported: liver disease, kidney disease, neurological issues.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential neonatal/childhood death, depending on the specific syndrome and affected organs.

+4. Severe perinatal asphyxia: Consistent with neonatal death and potential developmental abnormalities if the infant survives, depending on the severity and duration of oxygen deprivation.

+5. Prematurity complications: Consistent with neonatal death and potential developmental abnormalities, depending on the gestational age and complications experienced by the premature infant.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, growth delays, and potential organ involvement. Key symptoms like developmental delays or neurological issues may not be reported.

+2. Congenital malformation syndrome: Matches microcephaly, prenatal abnormalities, severe short stature, and potential organ involvement. Specific dysmorphic features or other congenital anomalies may not be reported.

+3. Lysosomal storage disorder: Consistent with growth delays, organ involvement (effusions), and potential neurological manifestations. Specific symptoms like coarse facial features or skeletal abnormalities may not be reported.

+4. Chromosomal disorder: Could explain microcephaly, prenatal abnormalities, growth restriction, and potential organ involvement. Specific dysmorphic features or intellectual disability may not be reported.

+5. Congenital infection or teratogen exposure: Matches prenatal abnormalities, growth restriction, and potential organ involvement. Specific maternal history or clinical findings may not be reported.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorders: Consistent with hyperammonemia, hyperglutaminemia, oroticaciduria, and potential death in childhood.

+2. Organic acidemias: Consistent with hyperammonemia and oroticaciduria, but hyperglutaminemia is less common.

+3. Liver disease: Consistent with hyperammonemia, but other reported symptoms are less typical.

+4. Reye's syndrome: Consistent with vomiting, hyperammonemia, and potential death in childhood, but hyperglutaminemia and oroticaciduria are not typical.

+5. Certain cancers: Hyperammonemia and metabolic abnormalities can occur, but the specific symptom combination is less common.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal tyrosine levels, elevated urinary carboxylic acids, developmental abnormalities, and potential early mortality. Key symptom not reported: intellectual disability or developmental delay.

+2. Maple Syrup Urine Disease (MSUD): Consistent with elevated urinary carboxylic acids, developmental abnormalities, and potential early mortality. Key symptoms not reported: maple syrup odor, lethargy, and metabolic acidosis.

+3. Congenital Hypothyroidism: Consistent with developmental abnormalities and obesity. Key symptoms not reported: constipation, dry skin, and delayed growth.

+4. Prader-Willi Syndrome: Consistent with developmental abnormalities, obesity, and potential early mortality. Key symptoms not reported: hypotonia, hypogonadism, and intellectual disability.

+5. Bardet-Biedl Syndrome: Consistent with developmental abnormalities, obesity, and potential early mortality. Key symptoms not reported: retinal dystrophy, polydactyly, and renal abnormalities.",Hereditary metabolic disorders
['Pearson syndrome'],"+1. Mitochondrial disease: Consistent with metabolic acidosis, neurological symptoms, multi-organ dysfunction, and potential energy deficiency. Key symptoms not reported: muscle weakness, exercise intolerance, and seizures.

+2. Inborn error of metabolism: Consistent with metabolic acidosis, hypoglycemia, and abnormal metabolite levels. Key symptoms not reported: specific metabolic derangements or organ-specific manifestations.

+3. Congenital syndrome or chromosomal abnormality: Consistent with multi-system involvement and congenital nature. Key symptoms not reported: specific dysmorphic features or developmental delays.

+4. Immunodeficiency disorder: Consistent with recurrent viral infections and hematological abnormalities. Key symptoms not reported: specific infections or lymphocyte abnormalities.

+5. Malignancy: Consistent with multi-organ dysfunction and metabolic disturbances. Key symptoms not reported: specific tumor markers or localized mass lesions.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with broad/long/deep philtrum, anteverted nares, syndactyly, generalized hypotonia, hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration. Feeding difficulties and neonatal/infant death can occur in severe cases.

+2. Trisomy 18 (Edwards syndrome): Consistent with broad/long/deep philtrum, anteverted nares, syndactyly, generalized hypotonia, neonatal death, death in infancy, feeding difficulties. Does not typically involve cholesterol abnormalities.

+3. Zellweger syndrome: Consistent with broad/long/deep philtrum, anteverted nares, generalized hypotonia, feeding difficulties. Does not typically involve cholesterol abnormalities or syndactyly.

+4. Fetal alcohol spectrum disorder (FASD): Consistent with broad/long/deep philtrum, anteverted nares, generalized hypotonia, feeding difficulties. Does not typically involve syndactyly or cholesterol abnormalities.

+5. Congenital disorder of glycosylation (CDG): Consistent with generalized hypotonia, feeding difficulties. May involve some physical features, but cholesterol abnormalities are not characteristic.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Cystic fibrosis: Consistent with recurrent viral infections, vomiting, and abdominal pain. Historically led to early childhood death before modern treatments.

+2. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and early childhood death. Gastrointestinal symptoms are not typical.

+3. Chronic granulomatous disease (CGD): Consistent with recurrent viral infections and early childhood death. Gastrointestinal symptoms are not typical.

+4. Galactosemia: Consistent with vomiting, abdominal pain, and potentially early childhood death if undiagnosed. Recurrent infections are not a typical symptom.

+5. Intestinal malrotation: Consistent with vomiting and abdominal pain. Recurrent infections and early childhood death are not typical symptoms.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Argininemia: Consistent with hyperammonemia, argininuria, and abnormal circulating arginine concentration. May not present with hyperglycinuria or hyperglutaminemia.

+2. Citrullinemia: Consistent with hyperammonemia and elevated plasma citrulline. May not present with argininuria or abnormal circulating arginine concentration.

+3. Ornithine transcarbamylase deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. May not present with specific amino acid abnormalities.

+4. Carbamoyl phosphate synthetase I deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. May not present with specific amino acid abnormalities.

+5. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with hyperglycinuria. Does not typically present with hyperammonemia or other amino acid abnormalities.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, lethargy, hypotonia, developmental delay, and other symptoms.

+2. Propionic acidemia: Consistent with lethargy, hypotonia, developmental delay, and metabolic acidosis. Key symptom not reported: protein avoidance.

+3. Homocystinuria: Consistent with hyperhomocystinemia, developmental delay, and hypotonia. Key symptoms not reported: ectopia lentis, skeletal abnormalities.

+4. Urea cycle disorder: Consistent with hyperammonemia, lethargy, and developmental delay. Key symptoms not reported: cyclical vomiting, protein intolerance.

+5. Fatty acid oxidation disorder: Consistent with lethargy, hypotonia, and metabolic decompensation. Key symptoms not reported: hypoketotic hypoglycemia, cardiomyopathy.",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Urea cycle disorder: Hyperammonemia, abnormal amino acid levels (aspartate family, alanine), potential for neonatal/early childhood death. Key symptom not reported: cyclical vomiting, lethargy.

+2. Fatty acid oxidation disorder: Decreased plasma free carnitine, hypotonia, metabolic decompensation. Key symptom not reported: hypoketotic hypoglycemia, hepatomegaly.

+3. Organic acidemia: Hyperammonemia, hypotonia, metabolic crises. Key symptom not reported: ketoacidosis, developmental delay.

+4. Mitochondrial disorder: Hypotonia, potential for neonatal/early childhood death. Key symptoms not reported: lactic acidosis, seizures, neurological regression.

+5. Carnitine transporter deficiency: Decreased plasma free carnitine, hypotonia, metabolic decompensation. Key symptom not reported: cardiomyopathy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, potential developmental abnormalities, and neonatal death are consistent with this diagnosis. Key symptoms not reported: specific metabolic abnormalities or organ involvement.

+2. Congenital airway anomaly: Upper airway obstruction and potential neonatal death are consistent with this diagnosis. Key symptoms not reported: specific anatomical defects or associated anomalies.

+3. Chromosomal abnormality or genetic syndrome: Abnormality of prenatal development or birth, potential developmental abnormalities, and multi-system involvement are consistent with this diagnosis. Key symptoms not reported: specific chromosomal or genetic defect.

+4. Severe respiratory disorder: Chronic pulmonary obstruction, upper airway obstruction, and potential neonatal death are consistent with this diagnosis. Key symptoms not reported: specific respiratory pathology or underlying cause.

+5. Congenital heart defect: Abnormality of prenatal development or birth, potential developmental abnormalities, and neonatal death are consistent with this diagnosis. Key symptoms not reported: specific cardiac defect or associated anomalies.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism (e.g., fatty acid oxidation disorder, organic acidemia): Consistent with decreased plasma free carnitine, decreased 3-hydroxyacyl-CoA dehydrogenase level, abnormal vitamin B12 concentration, hypoxemia, and early mortality. May not fully explain spasticity or gastrointestinal symptoms.

+2. Congenital malformation/chromosomal abnormality: Consistent with premature birth, early mortality, and multi-system involvement (neurological, gastrointestinal, metabolic). Specific malformation or syndrome would need to be identified based on additional testing.

+3. Severe perinatal complication (e.g., hypoxic-ischemic encephalopathy, sepsis): Consistent with premature birth, hypoxemia, and early mortality. May not fully explain metabolic abnormalities or gastrointestinal symptoms.

+4. Neuromuscular disorder (e.g., spinal muscular atrophy, muscular dystrophy): Consistent with spasticity and early mortality. May not fully explain metabolic abnormalities or gastrointestinal symptoms.

+5. Mitochondrial disorder: Consistent with multi-system involvement (neurological, gastrointestinal, metabolic), hypoxemia, and early mortality. Specific mitochondrial disorder would need to be identified based on additional testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Consistent with hypertyrosinemia and potential for early death. May not explain hyperphenylalaninemia or recurrent viral infections.

+2. Leukodystrophy: Consistent with potential for early death and neurological involvement. May not explain metabolic abnormalities or recurrent viral infections.

+3. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Does not typically present with hypertyrosinemia or recurrent viral infections.

+4. Combined metabolic and immunodeficiency disorder: Consistent with metabolic abnormalities, recurrent viral infections, and potential for early death. Specific disorder would need further investigation.

+5. Undiagnosed inherited metabolic disorder: Consistent with metabolic abnormalities and potential for early death. May not fully explain the combination of symptoms reported.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with aminoaciduria, abnormal circulating glycine concentration, and elevated urinary carboxylic acid. Key symptom not reported: severe neurological symptoms, such as seizures and developmental delays.

+2. Methylmalonic acidemia: An organic acidemia consistent with aminoaciduria and elevated urinary carboxylic acid. Key symptoms not reported: lethargy, vomiting, and metabolic acidosis.

+3. Propionic acidemia: Another organic acidemia that can present with aminoaciduria, elevated urinary carboxylic acid, and potentially abnormal glycine levels. Key symptoms not reported: metabolic acidosis, vomiting, and developmental delays.

+4. Isovaleric acidemia: An organic acidemia characterized by aminoaciduria, elevated carboxylic acids, and potentially abnormal glycine levels. Key symptom not reported: a distinctive ""sweaty feet"" odor.

+5. Glutaric acidemia type I: An organic acidemia that can cause aminoaciduria, elevated carboxylic acids, and potentially abnormal glycine levels. Key symptoms not reported: macrocephaly (enlarged head size) and neurological manifestations.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Leukodystrophy: Consistent with delayed speech/language development, seizures, ataxia, motor delay, generalized hypotonia, and elevated urinary carboxylic acid. May not involve hyperactivity.

+2. Mitochondrial disorder: Consistent with seizures, ataxia, motor delay, generalized hypotonia, and elevated urinary carboxylic acid. Hyperactivity and speech/language delays are less common.

+3. Angelman syndrome: Consistent with delayed speech/language development, hyperactivity, seizures, ataxia, motor delay, and generalized hypotonia. Does not typically involve elevated carboxylic acids or early death.

+4. Autism spectrum disorder: Consistent with delayed speech/language development, hyperactivity, and motor delay. Does not typically involve seizures, ataxia, hypotonia, or elevated carboxylic acids.

+5. Unspecified neurodegenerative disorder: Consistent with delayed speech/language development, seizures, ataxia, motor delay, generalized hypotonia, and potential early death. Elevated carboxylic acid and hyperactivity may or may not be present.",Hereditary metabolic disorders
['Argininosuccinic aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, vomiting, tachypnea, and potentially hepatomegaly. Key symptom not reported: hypoglycemia.

+2. Fatty acid oxidation disorder: Consistent with metabolic acidosis, vomiting, hepatomegaly, tachypnea. Key symptoms not reported: hypoglycemia, lethargy.

+3. Congenital heart defect: Consistent with tachycardia, potentially contributing to metabolic acidosis and other symptoms. Key symptom not reported: cyanosis or heart murmur.

+4. Biliary atresia: Consistent with hepatomegaly, vomiting, and potentially metabolic disturbances. Key symptom not reported: jaundice or pale stools.

+5. Chromosomal or genetic disorder: Consistent with multiple system involvement and severe symptoms from birth. Specific diagnosis would depend on genetic testing results.",Hereditary metabolic disorders
['Gyrate atrophy of choroid and retina'],"+1. Maple syrup urine disease (MSUD): Consistent with hyperammonemia, hyperglycinemia, hypoargininemia, hyperornithinemia, abnormal circulating serine concentration, feeding difficulties, and potential for severe complications and early death if untreated.

+2. Methylmalonic acidemia: Consistent with hyperammonemia, anemia, and potential for severe complications and early death if untreated. May not fully explain all amino acid abnormalities reported.

+3. Cystinosis: Consistent with short stature, amino acid abnormalities, and potential for severe complications if untreated. Blindness and other symptoms may not be typical.

+4. Inherited retinal dystrophy or optic nerve disorder: Consistent with blindness, but does not explain the metabolic and growth-related symptoms.

+5. Malabsorption syndrome (e.g., cystic fibrosis, celiac disease): Consistent with malabsorption and feeding difficulties, but does not typically cause the amino acid abnormalities or severe growth impairment reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential developmental abnormalities/early death if untreated. Key symptom not reported: intellectual disability.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential developmental abnormalities/early death if untreated. Key symptoms not reported: liver disease, kidney disease, neurological issues.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential neonatal/childhood death, depending on the specific syndrome and severity.

+4. Severe perinatal asphyxia: Consistent with neonatal death and potential developmental abnormalities if the infant survives, depending on the extent of brain injury.

+5. Prematurity complications: Consistent with neonatal death and potential developmental abnormalities, depending on the degree of prematurity and associated complications.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, cerebral edema, neonatal death/death in infancy. May not exhibit generalized hypotonia or feeding difficulties in all cases.

+2. Organic acidemia: Consistent with hyperammonemia, cerebral edema, neonatal death/death in infancy. May not exhibit generalized hypotonia or feeding difficulties in all cases.

+3. Mitochondrial disorder: Consistent with generalized hypotonia, feeding difficulties, and potential for progressive neurological deterioration. Hyperammonemia and cerebral edema are less typical.

+4. Leigh syndrome: Consistent with generalized hypotonia, feeding difficulties, and potential for progressive neurological deterioration. Hyperammonemia and cerebral edema are less typical.

+5. Lysosomal storage disorder: Consistent with generalized hypotonia and feeding difficulties. Hyperammonemia, cerebral edema, and neonatal death/death in infancy are less typical.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Consistent with abnormal myelination, seizures, motor delay, hypotonia, blindness, and hearing impairment. May not explain abnormal amino acid levels.

+2. Peroxisomal disorder: Consistent with neurological symptoms, vision and hearing loss, and abnormal amino acid levels. May not explain severe myelination abnormalities.

+3. Mitochondrial disorder: Consistent with seizures, neurological symptoms, and abnormal amino acid levels. May not explain severe vision and hearing loss.

+4. Lysosomal storage disorder: Consistent with progressive neurological deterioration, seizures, vision and hearing loss. May not explain abnormal amino acid levels.

+5. Inherited metabolic disorder: Consistent with abnormal amino acid levels and neurological symptoms. Specific type may depend on additional test results.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Congenital brain malformation or genetic disorder: Hydrocephalus, microcephaly, intellectual disability, strabismus, nystagmus, premature birth, respiratory insufficiency, death in infancy/childhood.

+2. Methylmalonic acidemia: Hyperhomocystinemia, methylmalonic aciduria, intellectual disability, respiratory insufficiency, death in infancy/childhood. May not exhibit hydrocephalus or microcephaly.

+3. Homocystinuria: Hyperhomocystinemia, intellectual disability, strabismus, nystagmus, dyskinesia. May not exhibit hydrocephalus, microcephaly, or methylmalonic aciduria.

+4. Neurodegenerative disorder: Intellectual disability, strabismus, nystagmus, dyskinesia. May not exhibit hydrocephalus, microcephaly, or metabolic abnormalities.

+5. Complications of prematurity: Premature birth, respiratory insufficiency, death in infancy/childhood. May not exhibit hydrocephalus, microcephaly, or metabolic abnormalities.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with vomiting, gastrointestinal inflammation, abnormal carnitine levels, and decreased 3-hydroxyacyl-CoA dehydrogenase. May present with metabolic crisis, hypoglycemia, and liver dysfunction.

+2. Organic acidemia: Consistent with vomiting, gastrointestinal inflammation, and metabolic abnormalities. Specific organic acids may accumulate, leading to metabolic acidosis and other complications.

+3. Carnitine deficiency disorder: Consistent with abnormal carnitine levels and potential metabolic decompensation. May present with hypoketotic hypoglycemia, cardiomyopathy, and muscle weakness.

+4. Mitochondrial disorder: Consistent with multisystem involvement, including gastrointestinal symptoms and metabolic abnormalities. May present with lactic acidosis, neurological symptoms, and organ dysfunction.

+5. Congenital disorder of glycosylation: Although not directly indicated by the reported symptoms, these disorders can affect multiple organ systems and present with gastrointestinal and metabolic abnormalities.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Urea cycle disorder: Consistent with hypotonia, metabolic acidosis, hyperammonemia, and early death. Key symptom not reported: elevated levels of specific amino acids or urea cycle metabolites.

+2. Organic acidemia: Consistent with hypotonia, metabolic acidosis, and early death. Key symptom not reported: elevated levels of specific organic acids.

+3. Mitochondrial disorder: Consistent with hypotonia, metabolic acidosis, and early death. Key symptom not reported: lactic acidosis or other specific biochemical abnormalities.

+4. Congenital myopathy: Consistent with generalized hypotonia and early death. Key symptoms not reported: specific muscle biopsy findings or genetic mutations.

+5. Severe combined immunodeficiency (SCID): Consistent with leukopenia. Key symptoms not reported: recurrent infections, failure to thrive, or specific immunological abnormalities.",Hereditary metabolic disorders
['Tyrosinemia type 2'],"+1. Richner-Hanhart syndrome: Consistent with keratitis, conjunctivitis, photophobia, hyperkeratosis, intellectual disability, seizures, and death in childhood. Key symptom not reported: palmoplantar keratoderma (thickening of skin on palms and soles).

+2. Tyrosinemia type II: Consistent with keratitis, conjunctivitis, photophobia, hyperkeratosis, intellectual disability, seizures, hypertyrosinemia, and death in childhood. Key symptom not reported: painful palmoplantar keratosis.

+3. Vernal keratoconjunctivitis: Consistent with keratitis, conjunctivitis, photophobia, and epiphora. Key symptoms not reported: itching, eye discharge, and seasonal exacerbation.

+4. Herpes simplex keratitis: Consistent with keratitis, conjunctivitis, photophobia, and epiphora. Key symptoms not reported: eye pain, blurred vision, and history of herpes simplex virus infection.

+5. Stevens-Johnson syndrome: Consistent with keratitis, conjunctivitis, photophobia, and hyperkeratosis. Key symptoms not reported: widespread skin rash, mucosal involvement, and fever.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal tyrosine levels, and potential complications leading to death in infancy or early adulthood if untreated. Key symptom not reported: intellectual disability or developmental delays.

+2. Maple syrup urine disease (MSUD): Consistent with abnormal tyrosine levels, potential developmental delays, and risk of death in infancy or early childhood if untreated. Key symptom not reported: maple syrup odor in urine or sweat.

+3. Tyrosinemia: Consistent with abnormal tyrosine levels and potential complications leading to early death if untreated. Key symptom not reported: liver dysfunction or failure.

+4. Congenital disorders of glycosylation (CDG): Consistent with abnormality of prenatal development, potential developmental delays, and risk of early death in severe cases. Key symptom not reported: specific clinical features depending on the type of CDG.

+5. Inborn errors of metabolism: Consistent with a combination of reported symptoms, including abnormal amino acid levels, developmental issues, and potential life-threatening complications. Key symptom not reported: specific clinical features depending on the type of metabolic disorder.",Hereditary metabolic disorders
[],"+1. Urea cycle disorder: Consistent with hyperammonemia, cyanosis, seizures, and potential for neonatal death. Key symptom not reported: vomiting, lethargy.

+2. Organic acidemia: Matches 3-hydroxydicarboxylic aciduria, hyperammonemia, seizures, and potential for early death. Key symptom not reported: developmental delays.

+3. Mitochondrial disorder: Consistent with cyanosis, seizures, and potential for early death due to impaired energy production. Key symptoms not reported: muscle weakness, vision/hearing problems.

+4. Fatty acid oxidation disorder: Matches cyanosis, seizures, and potential for early death due to impaired energy production. Key symptom not reported: hypoglycemia.

+5. Glycogen storage disease: Consistent with seizures and potential for early death due to impaired energy production. Key symptoms not reported: enlarged liver, muscle cramps.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Metabolic disorder: Consistent with vomiting, dark urine, and potential death in infancy if untreated. Key symptoms like lethargy, poor feeding, or developmental delays may also be present.

+2. Biliary atresia: Consistent with dark urine (jaundice), vomiting, and potential liver failure leading to death in infancy if not treated. Pale stools and abdominal distension may also occur.

+3. Congenital infection: Consistent with vomiting, dark urine (jaundice), and potential severe complications in infancy. Additional symptoms like rash, hearing loss, or neurological abnormalities may be present depending on the specific infection.

+4. Pyloric stenosis: Consistent with persistent vomiting, which can lead to dehydration and dark urine. Infants may also exhibit projectile vomiting and a palpable abdominal mass.

+5. Congenital brain or spinal cord abnormality: Consistent with vomiting and potential life-threatening complications in infancy. Additional symptoms like seizures, developmental delays, or neurological deficits may be present depending on the specific abnormality.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, elevated urinary carboxylic acid, seizures, lethargy, growth delay, metabolic acidosis, and developmental delays. Key symptom not reported: maple syrup odor in urine and sweat.

+2. Organic acidemia: Consistent with metabolic acidosis, lethargy, seizures, growth delay, and elevated urinary carboxylic acid. Specific type of organic acidemia would need to be determined based on further testing.

+3. Urea cycle disorder: Consistent with hyperammonemia, lethargy, seizures, and metabolic acidosis. Specific disorder (e.g., ornithine transcarbamylase deficiency) would need to be identified through additional testing.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, lethargy, seizures, and developmental delays. Further testing would be needed to identify the specific mitochondrial defect.

+5. Leukodystrophy: Consistent with neurological symptoms (seizures, lethargy, drowsiness), developmental delays, and severe hearing impairment. However, the metabolic abnormalities are not typical of leukodystrophies.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, hyperglutaminemia, cerebral edema, and potential neonatal onset. Key symptom not reported: elevated plasma citrulline levels.

+2. Organic acidemia: Consistent with metabolic derangements (hypoglycemia, abnormal amino acid levels), neurological symptoms, and potential neonatal onset. Key symptom not reported: specific organic acid elevations in urine or blood.

+3. Mitochondrial disorder: Consistent with multi-system involvement (neurological, metabolic, gastrointestinal), progressive nature, and potential neonatal onset. Key symptom not reported: lactic acidosis or specific enzyme deficiencies.

+4. Severe combined immunodeficiency: Consistent with recurrent viral infections, gastrointestinal inflammation, and potential complications like myocarditis. Key symptom not reported: specific lymphocyte subset abnormalities.

+5. Leukodystrophy: Consistent with progressive neurological symptoms, potential neonatal onset, and abnormal metabolic findings. Key symptom not reported: specific white matter abnormalities on brain imaging.",Hereditary metabolic disorders
